<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?>
<?SourceDTD.Version 1.1?>
<?ConverterInfo.XSLTName jats-oasis2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Cancer Med</journal-id>
    <journal-id journal-id-type="iso-abbrev">Cancer Med</journal-id>
    <journal-id journal-id-type="doi">10.1002/(ISSN)2045-7634</journal-id>
    <journal-id journal-id-type="publisher-id">CAM4</journal-id>
    <journal-title-group>
      <journal-title>Cancer Medicine</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2045-7634</issn>
    <publisher>
      <publisher-name>John Wiley and Sons Inc.</publisher-name>
      <publisher-loc>Hoboken</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9636515</article-id>
    <article-id pub-id-type="pmid">35575002</article-id>
    <article-id pub-id-type="doi">10.1002/cam4.4717</article-id>
    <article-id pub-id-type="publisher-id">CAM44717</article-id>
    <article-id pub-id-type="other">CAM4-2021-11-4994.R2</article-id>
    <article-categories>
      <subj-group subj-group-type="overline">
        <subject>Method</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Method</subject>
        <subj-group subj-group-type="heading">
          <subject>Bioinformatics</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>A practical framework <styled-content style="fixed-case" toggle="no">RNMF</styled-content> for exploring the association between mutational signatures and genes using gene cumulative contribution abundance</article-title>
      <alt-title alt-title-type="left-running-head">Li et al.</alt-title>
    </title-group>
    <contrib-group>
      <contrib id="cam44717-cr-0001" contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Zhenzhang</given-names>
        </name>
        <xref rid="cam44717-aff-0001" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="cam44717-aff-0002" ref-type="aff">
          <sup>2</sup>
        </xref>
        <xref rid="cam44717-aff-0003" ref-type="aff">
          <sup>3</sup>
        </xref>
      </contrib>
      <contrib id="cam44717-cr-0002" contrib-type="author" corresp="yes">
        <name>
          <surname>Liang</surname>
          <given-names>Haihua</given-names>
        </name>
        <xref rid="cam44717-aff-0001" ref-type="aff">
          <sup>1</sup>
        </xref>
        <address>
          <email>lianghhgdin@126.com</email>
        </address>
      </contrib>
      <contrib id="cam44717-cr-0003" contrib-type="author" corresp="yes">
        <name>
          <surname>Zhang</surname>
          <given-names>Shaoan</given-names>
        </name>
        <xref rid="cam44717-aff-0001" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="cam44717-aff-0002" ref-type="aff">
          <sup>2</sup>
        </xref>
        <address>
          <email>zsagdut2016@yeah.net</email>
        </address>
      </contrib>
      <contrib id="cam44717-cr-0004" contrib-type="author" corresp="yes">
        <name>
          <surname>Luo</surname>
          <given-names>Wen</given-names>
        </name>
        <xref rid="cam44717-aff-0001" ref-type="aff">
          <sup>1</sup>
        </xref>
        <address>
          <email>526478063@qq.com</email>
        </address>
      </contrib>
    </contrib-group>
    <aff id="cam44717-aff-0001">
      <label>
        <sup>1</sup>
      </label>
      <institution>College of Mathematics and Systems Science, Guangdong Polytechnic Normal University</institution>
      <city>Guangzhou</city>
      <country country="CN">China</country>
    </aff>
    <aff id="cam44717-aff-0002">
      <label>
        <sup>2</sup>
      </label>
      <named-content content-type="organisation-division">School of Basic Medical Sciences</named-content>
      <institution>Guangzhou Medical University</institution>
      <city>Guangzhou</city>
      <country country="CN">China</country>
    </aff>
    <aff id="cam44717-aff-0003">
      <label>
        <sup>3</sup>
      </label>
      <institution>Cloud and Gene AI Research Institute</institution>
      <city>Guangzhou</city>
      <country country="CN">China</country>
    </aff>
    <author-notes>
      <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Haihua Liang, Shaoan Zhang and Wen Luo, College of Mathematics and Systems Science, Guangdong Polytechnic Normal University. No. 293, Zhongshan Avenue West, Tianhe District, Guangzhou, 510665, China.<break/>
Email: <email>lianghhgdin@126.com</email> (H. L.); Email: <email>zsagdut2016@yeah.net</email> (S. Z.); Email: <email>526478063@qq.com</email> (W. L.)<break/>
</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>16</day>
      <month>5</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="collection">
      <month>11</month>
      <year>2022</year>
    </pub-date>
    <volume>11</volume>
    <issue seq="130">21</issue>
    <issue-id pub-id-type="doi">10.1002/cam4.v11.21</issue-id>
    <fpage>4053</fpage>
    <lpage>4069</lpage>
    <history>
      <date date-type="rev-recd">
        <day>04</day>
        <month>3</month>
        <year>2022</year>
      </date>
      <date date-type="received">
        <day>27</day>
        <month>11</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>14</day>
        <month>3</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <!--&#x000a9; 2022 Published by John Wiley & Sons Ltd.-->
      <copyright-statement content-type="article-copyright">© 2022 The Authors. <italic toggle="yes">Cancer Medicine</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri content-type="pdf" xlink:href="file:CAM4-11-4053.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="cam44717-sec-0001">
        <title>Background</title>
        <p>Mutational signatures are somatic mutation patterns enriching operational mutational processes, which can provide abundant information about the mechanism of cancer. However, understanding of the pathogenic biological processes is still limited, such as the association between mutational signatures and genes.</p>
      </sec>
      <sec id="cam44717-sec-0002">
        <title>Methods</title>
        <p>We developed a simple and practical <italic toggle="no">R</italic> package called <italic toggle="no">RNMF</italic> (<ext-link xlink:href="https://github.com/zhenzhang-li/RNMF" ext-link-type="uri">https://github.com/zhenzhang‐li/RNMF</ext-link>) for mutational signature analysis, including a key model of cumulative contribution abundance (CCA), which was designed to highlight the association between mutational signatures and genes and then applying it to a meta‐analysis of 1073 individuals with esophageal squamous cell carcinoma (ESCC).</p>
      </sec>
      <sec id="cam44717-sec-0003">
        <title>Results</title>
        <p>We revealed a number of known and previously undescribed SBS or ID signatures, and we found that APOBEC signatures (SBS2* and SBS13*) were closely associated with <italic toggle="no">PIK3CA</italic> mutation, especially the E545k mutation. Furthermore, we found that age signature is closely related to the frequent mutation of <italic toggle="no">TP53,</italic> of which R342* is highlighted due to strongly linked to age signature. In addition, the CCA matrix image data of genes in the signatures New, SBS3*, and SBS17b* were helpful for the preliminary evaluation of shortened survival outcome. These results can be extended to estimate the distribution of mutations or features, and study the potential impact of clinical factors.</p>
      </sec>
      <sec id="cam44717-sec-0004">
        <title>Conclusions</title>
        <p>In a word, <italic toggle="no">RNMF</italic> can successfully achieve the correlation analysis of mutational signatures and genes, proving a strong theoretical basis for the study of mutational processes during tumor development.</p>
      </sec>
    </abstract>
    <abstract abstract-type="graphical">
      <p>1. We successfully developed a method of mutation feature map analysis, including the CCA (cumulative contribution abundance) model, which can highlight the association between genes and mutational signatures. 2. It was found that APOBEC signal mediates the occurrence of PIK3CA <italic toggle="yes">E545k</italic> mutation. 3. It was confirmed that age characteristics are closely related to the <italic toggle="yes">TP53</italic> R342* mutation.<boxed-text position="anchor" content-type="graphic" id="cam44717-blkfxd-0001"><graphic xlink:href="CAM4-11-4053-g005.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p>
    </abstract>
    <kwd-group kwd-group-type="author-generated">
      <kwd id="cam44717-kwd-0001">cumulative contribution abundance</kwd>
      <kwd id="cam44717-kwd-0002">esophageal squamous cell carcinoma</kwd>
      <kwd id="cam44717-kwd-0003">mutational signature</kwd>
      <kwd id="cam44717-kwd-0004">RNMF</kwd>
    </kwd-group>
    <funding-group>
      <award-group id="funding-0001">
        <funding-source>Science and technology planning project of guangzhou</funding-source>
        <award-id>006259497026</award-id>
      </award-group>
      <award-group id="funding-0002">
        <funding-source>The project of promoting research capabilities for key constructed disciplines in Guangdong Province</funding-source>
        <award-id>2021ZDJS028</award-id>
      </award-group>
      <award-group id="funding-0003">
        <funding-source>The project of young creative talents of department education of Guangdong (Natural Science)</funding-source>
        <award-id>2019KQNCX067</award-id>
      </award-group>
      <award-group id="funding-0004">
        <funding-source>The NNSF of China, NNSF of Guangdong Province (2021)</funding-source>
        <award-id>11771101</award-id>
      </award-group>
    </funding-group>
    <counts>
      <fig-count count="8"/>
      <table-count count="1"/>
      <page-count count="17"/>
      <word-count count="10302"/>
    </counts>
    <custom-meta-group>
      <custom-meta>
        <meta-name>source-schema-version-number</meta-name>
        <meta-value>2.0</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>cover-date</meta-name>
        <meta-value>November 2022</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>details-of-publishers-convertor</meta-name>
        <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.0 mode:remove_FC converted:05.11.2022</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
  <notes>
    <p content-type="self-citation">
      <mixed-citation publication-type="journal" id="CAM44717-cit-2001"><string-name><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name><surname>Liang</surname><given-names>H</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name><surname>Luo</surname><given-names>W</given-names></string-name>. <article-title>A practical framework <styled-content style="fixed-case" toggle="no">RNMF</styled-content> for exploring the association between mutational signatures and genes using gene cumulative contribution abundance</article-title>. <source>Cancer Med</source>. <year>2022</year>;<volume>11</volume>(<issue>21</issue>):<fpage>4053</fpage>‐<lpage>4069</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cam4.4717</pub-id></mixed-citation>
    </p>
  </notes>
</front>
<body id="cam44717-body-0001">
  <sec id="cam44717-sec-0005">
    <label>1</label>
    <title>INTRODUCTION</title>
    <p>The cancer genomes contain many mutations, which are derived from exogenous and endogenous mutational processes that operate during the cell lineage.<xref rid="cam44717-bib-0001" ref-type="bibr"><sup>1</sup></xref> These mutational processes are cumulative effects of DNA damage and repair processes, indicating unique patterns in tumorigenesis, namely mutational signatures.<xref rid="cam44717-bib-0002" ref-type="bibr"><sup>2</sup></xref>, <xref rid="cam44717-bib-0003" ref-type="bibr"><sup>3</sup></xref>, <xref rid="cam44717-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="cam44717-bib-0005" ref-type="bibr"><sup>5</sup></xref> Each mutational process from a tumor may involve some particular signatures that their biological combination processes could induce a large number of mutations.<xref rid="cam44717-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="cam44717-bib-0007" ref-type="bibr"><sup>7</sup></xref> Via studying the completeness of these mutations and identifying the digital genomic footprints that contribute to the mutation characteristics of tumors, we can not only reveal the potential mutational process information, understand the carcinogenic mechanism of tumor occurrence and development but also provide biomarkers for early diagnosis, accurate cancer stratification and clinical response prediction, and realize individual treatment strategies.<xref rid="cam44717-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="cam44717-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="cam44717-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="cam44717-bib-0011" ref-type="bibr"><sup>11</sup></xref>, <xref rid="cam44717-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="cam44717-bib-0013" ref-type="bibr"><sup>13</sup></xref> Analysis of mutational signatures may reveal previously unknown mutation mechanisms and mysterious environmental exposure, such as herbal supplements containing aristolochic acid.<xref rid="cam44717-bib-0013" ref-type="bibr"><sup>13</sup></xref> However, understanding of the pathogenic biological processes is still limited. Therefore, to systematically describe the mutational process leading to cancer, it is necessary to decipher the mutational signatures from the somatic mutation catalog by using mathematical statistical methods,<xref rid="cam44717-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="cam44717-bib-0015" ref-type="bibr"><sup>15</sup></xref>, <xref rid="cam44717-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="cam44717-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="cam44717-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="cam44717-bib-0019" ref-type="bibr"><sup>19</sup></xref>, <xref rid="cam44717-bib-0020" ref-type="bibr"><sup>20</sup></xref>, <xref rid="cam44717-bib-0021" ref-type="bibr"><sup>21</sup></xref>, <xref rid="cam44717-bib-0022" ref-type="bibr"><sup>22</sup></xref>, <xref rid="cam44717-bib-0023" ref-type="bibr"><sup>23</sup></xref> the number of mutations that each feature in a single sample can be attributed to each feature, which annotate the probability of each mutation class in each tumor and the possibility of each feature producing.</p>
    <p>Currently, the final referenced mutational signatures are archived in the catalog of cancer of somatic mutations in cancer (COSMIC, <ext-link xlink:href="https://cancer.sanger.ac.uk/cosmic/signatures)" ext-link-type="uri">https://cancer.sanger.ac.uk/cosmic/signatures</ext-link>). Most of them are common in various tumors, of which are specific to a certain type of tumor, of which are part of normal cell biology, and of which are related to abnormal exposure or tumor progression.<xref rid="cam44717-bib-0024" ref-type="bibr"><sup>24</sup></xref>, <xref rid="cam44717-bib-0025" ref-type="bibr"><sup>25</sup></xref>, <xref rid="cam44717-bib-0026" ref-type="bibr"><sup>26</sup></xref>, <xref rid="cam44717-bib-0027" ref-type="bibr"><sup>27</sup></xref>, <xref rid="cam44717-bib-0028" ref-type="bibr"><sup>28</sup></xref>, <xref rid="cam44717-bib-0029" ref-type="bibr"><sup>29</sup></xref>, <xref rid="cam44717-bib-0030" ref-type="bibr"><sup>30</sup></xref>, <xref rid="cam44717-bib-0031" ref-type="bibr"><sup>31</sup></xref> They may be attributed to known environmental exposure and mutation processes, such as tobacco smoke, ultraviolet radiation, the activity of the APOBEC series of cyclobutylaminases, and DNA mismatch repair defects or mutations in POLE. Besides, as known to us, the association between genes and mutational signatures was confirmed, and much focus were paid to study the role of hotspot mutations in the formation of mutational signatures, which provides a good research idea for the mechanism of tumorigenesis and development. However, at present, there are few tools systematically and in‐depth mining the relationship between genes and mutational signatures,<xref rid="cam44717-bib-0032" ref-type="bibr"><sup>32</sup></xref>, <xref rid="cam44717-bib-0033" ref-type="bibr"><sup>33</sup></xref> which undoubtedly does not bring much convenience to the association between mutational signatures and genes.</p>
    <p>Here, we first used the <italic toggle="yes">R</italic> language to design a simple and convenient package <italic toggle="yes">RNMF</italic>, which can directly start from the mutation data set to realize the correlation analysis of mutational signatures. Then, we pooled 1073 samples from Asian ESCC population, and then used <italic toggle="yes">RNMF</italic> to verify the practicability of this method framework. During the analysis, we highlighted interesting correlations through association analysis with driving mutations. Finally, deep learning method is used to explore the cumulative contribution abundance (CCA) matrix image data of gene under fixed features, and hierarchical learning of prognosis is done.</p>
  </sec>
  <sec sec-type="materials-and-methods" id="cam44717-sec-0006">
    <label>2</label>
    <title>MATERIALS AND METHODS</title>
    <sec id="cam44717-sec-0007">
      <label>2.1</label>
      <title>Genomic data collection</title>
      <p>All somatic mutations were initially collected from the supplementary data of six previous studies (Table <xref rid="cam44717-supitem-0010" ref-type="supplementary-material">S1</xref>) comprising 1073 esophageal squamous cell carcinoma (ESCC) cases, including 508 genome‐wide data and 565 exon sequencing data.</p>
    </sec>
    <sec id="cam44717-sec-0008">
      <label>2.2</label>
      <title>R package link and parsing description</title>
      <p>In the analysis process of this software, somatic variants can be imported from a Variant Call Format (VCF) file or a Mutation Annotation Format (MAF) file. Then it relies on the Bioconductor library, such as BS.genome.Hsapiens.UCSC.hg19 or BS.genome.Hsapiens.UCSC.hg38, to acquire an information matrix of mutation types (single‐base substitutions [SBS], double‐base substitutions [DBS], and insertion and deletion mutation [ID]). Subsequently, the program extracts mutational signatures according to the generated data and finally obtains the result files. The R package is publicly available at <ext-link xlink:href="https://github.com/LuoLicgigjs/RNMF" ext-link-type="uri">https://github.com/zhenzhang‐li/RNMF</ext-link>. The detailed document file also provides some examples of commands usage. In addition, scripts for running the package will also be provided in the R package.</p>
    </sec>
    <sec id="cam44717-sec-0009">
      <label>2.3</label>
      <title>Optimal mutational signature extraction framework</title>
      <p>Alexandrov,<xref rid="cam44717-bib-0015" ref-type="bibr"><sup>15</sup></xref> an NMF software, was developed for decomposing the characteristic map based on MATLAB language long before. Subsequently, there were some related programs developed based on R language, such as SomaticSignatures.<xref rid="cam44717-bib-0016" ref-type="bibr"><sup>16</sup></xref> However, these two software only targeted SBS Signatures' analysis. Then SigProfilerExtractor, which was developed based on Python language, appeared, aiming to analyze the three characteristic maps such as SBS, DBS, and ID signatures. Quite fittingly, our designed RNMF software provides the ability to obtain the count matrix of SBS, DBS, and ID directly from mutation data sets by a function interface. To connect the result format obtained by this function more conveniently and select a more optimized initial value, we decided to build a new R interface based on NMF principle and generate the data result format required in downstream analysis. Therefore, based on the model definition in previous reports,<xref rid="cam44717-bib-0034" ref-type="bibr"><sup>34</sup></xref>, <xref rid="cam44717-bib-0035" ref-type="bibr"><sup>35</sup></xref> we can obtain a classical formula <italic toggle="yes">V</italic> = <italic toggle="yes">PS</italic> + <italic toggle="yes">E</italic>, which is used to extract the mutational signatures in human cancers. In this equation, <italic toggle="yes">V</italic> refers to the observation matrix with size <italic toggle="yes">M</italic> × <italic toggle="yes">N</italic>, of which <italic toggle="yes">M</italic> represents the observed characteristics, and <italic toggle="yes">N</italic> is the number of samples. Supposing the number of mutational signatures is <italic toggle="yes">K</italic>, then we can estimate a non‐negative mutational signature matrix <italic toggle="yes">P</italic> with size <italic toggle="yes">M</italic> × <italic toggle="yes">K</italic> and a non‐negative abundance fractions matrix <italic toggle="yes">S</italic> with size <italic toggle="yes">K</italic> × <italic toggle="yes">N</italic>. Simultaneously, error matrix <italic toggle="yes">E</italic> that refers to nonsystematic errors and sampling noise is calculated during the processing.</p>
      <p>For an observed mutational catalogs <italic toggle="yes">V</italic>, these <italic toggle="yes">K</italic> mutational signatures could be extracted by <italic toggle="yes">denovoNMF</italic> (Figure <xref rid="cam44717-fig-0001" ref-type="fig">1</xref>) as following:</p>
      <fig position="float" fig-type="FIGURE" id="cam44717-fig-0001">
        <label>FIGURE 1</label>
        <caption>
          <p>Overview of <italic toggle="yes">RNMF</italic> workflows. The automatic process can start from inputting mutation data files in MAF or VCF format to generate the necessary mutation type matrix, including single‐base substitution mutation types with 96 different contexts, 78 strand agnostic double‐base substitution mutation types, and a compilation of 83 different types of small insertion and deletion (ID) mutation types. Next, the process can use two program interfaces (<italic toggle="yes">denovoNMF</italic> and <italic toggle="yes">InverseNMF</italic>) for signature analysis to get the mutational profiles. Then, according to the clinical grouping, non‐silent mutation data and the list of genes to be studied, combined with P matrix and S matrix, the cumulative contribution abundance matrix of genes was calculated. At the same time, the corresponding image data are generated according to the specified order, and finally the training and analysis are carried out by machine learning or deep learning methods, so as to obtain the expected results</p>
        </caption>
        <graphic xlink:href="CAM4-11-4053-g006" position="anchor" id="jats-graphic-3"/>
      </fig>
      <p>Step 1 (Capture random matrices): We randomly generate matrices <italic toggle="yes">P</italic> (<italic toggle="yes">P</italic> ≥ 0) and <italic toggle="yes">S</italic> (<italic toggle="yes">S</italic> ≥ 0). Ideally, for a mutational signature, its components are basically fixed, so the sum of its standardized components is equal to 1; for one sample, the total of normalized abundance fractions for each mutational signature should be infinitely close to 1. Hence, here we require that <mml:math id="jats-math-1" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mi>m</mml:mi></mml:munder><mml:msub><mml:mi>P</mml:mi><mml:mi mathvariant="italic">mk</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mi>k</mml:mi></mml:munder><mml:msub><mml:mi>S</mml:mi><mml:mi mathvariant="italic">kn</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math>.</p>
      <p>Step 2 (Optimize the initial value): We apply resampling to obtain a new matrix <mml:math id="jats-math-2" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>V</mml:mi><mml:mo stretchy="true">˜</mml:mo></mml:mover><mml:mfenced close=")" open="("><mml:mrow><mml:mover accent="true"><mml:mi>V</mml:mi><mml:mo stretchy="true">˜</mml:mo></mml:mover><mml:mo>≈</mml:mo><mml:mi>V</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math> by using the Dirichlet distribution, and straighten matrices <italic toggle="yes">P</italic> and <italic toggle="yes">S</italic> by columns and then merge them into a solution vector <mml:math id="jats-math-3" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="bold">x</mml:mi></mml:mrow></mml:mrow></mml:math>. An optimized objective function <mml:math id="jats-math-4" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:munder><mml:mi>min</mml:mi><mml:mrow><mml:mi>P</mml:mi><mml:mo>,</mml:mo><mml:mi>S</mml:mi></mml:mrow></mml:munder><mml:mi>E</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi>P</mml:mi><mml:mo>,</mml:mo><mml:mi>S</mml:mi><mml:mo>,</mml:mo><mml:mi>α</mml:mi><mml:mo>,</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mfenced close="‖" open="‖"><mml:mrow><mml:mi>V</mml:mi><mml:mo>−</mml:mo><mml:mi mathvariant="italic">PS</mml:mi></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:mi>α</mml:mi><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>≠</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:munder><mml:msubsup><mml:mi>P</mml:mi><mml:mi>i</mml:mi><mml:mi>T</mml:mi></mml:msubsup><mml:msub><mml:mi>P</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mi>S</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math>which previously reported<xref rid="cam44717-bib-0034" ref-type="bibr"><sup>34</sup></xref> is used to find the best solution, where <italic toggle="yes">α</italic> and <italic toggle="yes">β</italic> are the parameters to control the accelerated convergence. After smoothing <mml:math id="jats-math-5" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi mathvariant="bold">x</mml:mi><mml:mo stretchy="true">˜</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:math>, the updated matrices <italic toggle="yes">P</italic> and <italic toggle="yes">S</italic> are restored according to the straightening rules. Finally, we generate a new initial mutational signature matrix <italic toggle="yes">P</italic> and a new initial abundance fraction matrix <italic toggle="yes">S</italic> through 20,000 iterations via referring to the previous implementation process.<xref rid="cam44717-bib-0015" ref-type="bibr"><sup>15</sup></xref>
</p>
      <p>Step 3 (Re‐updated the initial value): Perform Steps 1 and 2 for <mml:math id="jats-math-6" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi>I</mml:mi><mml:mo>≥</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math> iterations. Their errors generated by iterations are calculated by formula <mml:math id="jats-math-7" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>E</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mfenced close="‖" open="‖"><mml:mrow><mml:mi>V</mml:mi><mml:mo>−</mml:mo><mml:mi mathvariant="italic">PS</mml:mi></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mrow></mml:math>, and the results of the 5 items with the smallest error are selected. Then we apply the k‐means<xref rid="cam44717-bib-0036" ref-type="bibr"><sup>36</sup></xref> algorithm to the set of matrices <italic toggle="yes">P</italic> and <italic toggle="yes">S</italic> to cluster the data into <italic toggle="yes">K</italic> clusters, respectively. Subsequently, class‐center <mml:math id="jats-math-8" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>P</mml:mi><mml:mo stretchy="true">˜</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:math> and <mml:math id="jats-math-9" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>S</mml:mi><mml:mo stretchy="true">˜</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:math> are obtained. Similar to Step 2, we straighten them to calculate the optimal solution space and finally gain the excellent initial value.</p>
      <p>Step 4 (Rerun NMF): In this step, we still use the multiplicative update rules to generate the final matrix. The iterative model is as follows:<disp-formula id="cam44717-disp-0001"><mml:math id="jats-math-10" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mo linebreak="goodbreak">=</mml:mo><mml:mi>P</mml:mi><mml:mfrac><mml:msup><mml:mi mathvariant="italic">VS</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:msup><mml:mi mathvariant="italic">PSS</mml:mi><mml:mi>T</mml:mi></mml:msup></mml:mfrac><mml:mo>,</mml:mo><mml:mi>S</mml:mi><mml:mo linebreak="goodbreak">=</mml:mo><mml:mi>S</mml:mi><mml:mfrac><mml:mrow><mml:msup><mml:mi>P</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:msup><mml:mi>P</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:mi mathvariant="italic">PS</mml:mi><mml:mo>+</mml:mo><mml:mi>γ</mml:mi></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>
</p>
      <p>where <italic toggle="yes">γ</italic> is a parameter to control the accelerated convergence. Iterate until <italic toggle="yes">P</italic> and <italic toggle="yes">S</italic> convergence or until the maximum number of 100,000 iterations is reached.</p>
      <p>Step 5 (Build a solution space): Repeat the process of steps 1 to 5 with <mml:math id="jats-math-11" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>Ι</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:mfenced close=")" open="("><mml:mrow><mml:mover accent="true"><mml:mi>Ι</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:mo>≥</mml:mo><mml:mn>20</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math> times to generate a solution space for all the value of <mml:math id="jats-math-12" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>K</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi>K</mml:mi><mml:mo>∈</mml:mo><mml:msup><mml:mi>N</mml:mi><mml:mo>+</mml:mo></mml:msup></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math>. Then suitable selection in this solution space using the silhouette coefficient measure and error gradient. The criteria we chose are as follows: 1) stable, without sudden decline or relatively large gradient of descent and large width of confidence interval and 2) small standard error term and the gradient of standard error between adjacent classes tends to be gentle.</p>
      <p>After a series of analysis process, the final mutational profiles of each <italic toggle="yes">K</italic> clusters can be acquired. Follow the previous experience,<xref rid="cam44717-bib-0020" ref-type="bibr"><sup>20</sup></xref> we use the cosine similarity to determine the similarity between two mutational signature A and B.</p>
    </sec>
    <sec id="cam44717-sec-0010">
      <label>2.4</label>
      <title>Deriving the contribution of defined mutational signatures</title>
      <p>At the same time, we also developed a reversible method named <italic toggle="yes">InverseNMF</italic>, which can identify mutational signatures within a small data set or a single tumor sample. Previous reports<xref rid="cam44717-bib-0020" ref-type="bibr"><sup>20</sup></xref>, <xref rid="cam44717-bib-0033" ref-type="bibr"><sup>33</sup></xref> have confirmed the importance of such applications and provided another analytical strategy for tumor characteristic map studies.</p>
      <p>In this step, the <italic toggle="yes">P</italic> matrix is a user‐defined matrix (such as the signature matrix provided by COSMIC), and then a feasible sample contribution matrix <italic toggle="yes">S</italic> can be estimated iteratively by observing matrix <italic toggle="yes">V</italic>. The iterative model is as follows:<disp-formula id="cam44717-disp-0002"><mml:math id="jats-math-13" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo linebreak="goodbreak">=</mml:mo><mml:mi>S</mml:mi><mml:mfrac><mml:mrow><mml:msup><mml:mi>P</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:msup><mml:mi>P</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:mi mathvariant="italic">PS</mml:mi><mml:mo>+</mml:mo><mml:mi>γ</mml:mi></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>
</p>
      <p>where <italic toggle="yes">γ</italic> is a parameter to control the accelerated convergence. Iterate until <italic toggle="yes">S</italic> convergence or until the maximum number of 100,000,000 iterations is reached.</p>
    </sec>
    <sec id="cam44717-sec-0011">
      <label>2.5</label>
      <title>Mutational signature operative in <styled-content style="fixed-case" toggle="no">ESCC</styled-content>
</title>
      <p>We applied our framework to extract mutational signatures from 508 WGS samples of 1073 ESCC tumors. At the same time, the previously reported tool “<italic toggle="yes">SigProfilerExtractor</italic>”<xref rid="cam44717-bib-0023" ref-type="bibr"><sup>23</sup></xref> was used to analyze the data. Finally, the similarity between the two results was analyzed (Figure <xref rid="cam44717-supitem-0001" ref-type="supplementary-material">S1</xref>). Our framework optimizes the non negative matrix factorization (NMF) algorithm and takes the change of silhouette coefficient and error gradient as the evaluation index of feature number selection (Figure <xref rid="cam44717-supitem-0002" ref-type="supplementary-material">S2</xref>). Here, the threshold is set to 0.9.</p>
      <p>To analyze and explore the potential features of exons of 1073 ESCC samples, We used COSMIC Mutational Signatures (v3.2 ‐ March 2021 and v2.0 ‐ March 2015) and mutational signals extracted from 508 WGS data as the background to obtain the number of mutations in each mutational signatures. Based on the results of three single base mutation data sets (508‐WGS cohort renames as WGS508, exon region of 508‐WGS cohort renames as EXON508, and exon region of 1073 samples renames as EXON1073), the eigenvalues of mutational signatures for subsequent analysis of ESCC were determined.</p>
    </sec>
    <sec id="cam44717-sec-0012">
      <label>2.6</label>
      <title>Cumulative contribution abundance of genes</title>
      <p>As described earlier,<xref rid="cam44717-bib-0007" ref-type="bibr"><sup>7</sup></xref> because each mutational process takes into account the mutation category and the generation of mutations in tumor is attributed to each corresponding process, we define that the influence of mutations of category <mml:math id="jats-math-14" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:mrow></mml:math> in tumor <mml:math id="jats-math-15" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:mrow></mml:math> during the mutational process can be expressed as:<disp-formula id="cam44717-disp-0003"><mml:math id="jats-math-16" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>φ</mml:mi><mml:mfenced close=")" open="("><mml:mi mathvariant="italic">mn</mml:mi></mml:mfenced><mml:mo linebreak="goodbreak">=</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>K</mml:mi></mml:munderover><mml:msub><mml:mi>P</mml:mi><mml:mi mathvariant="italic">mk</mml:mi></mml:msub><mml:msub><mml:mi>S</mml:mi><mml:mi mathvariant="italic">kn</mml:mi></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>where the unit <italic toggle="yes">P</italic>
<sub><italic toggle="yes">mk</italic></sub>
<italic toggle="yes">S</italic>
<sub><italic toggle="yes">kn</italic></sub> represents the influence of mutations of category <italic toggle="yes">m</italic> attributed to signature <italic toggle="yes">k</italic> in tumor <italic toggle="yes">n</italic>. Then the probability effects in mutations of category <italic toggle="yes">m</italic> due to signature <italic toggle="yes">k</italic> in tumor <italic toggle="yes">n</italic> can be expressed as:<disp-formula id="cam44717-disp-0004"><mml:math id="jats-math-17" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>ρ</mml:mi><mml:mfenced close=")" open="("><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mspace width="0.1pc"/><mml:mi mathvariant="italic">mn</mml:mi></mml:mfenced><mml:mo linebreak="goodbreak">=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mi mathvariant="italic">ms</mml:mi></mml:msub><mml:msub><mml:mi>S</mml:mi><mml:mi mathvariant="italic">sn</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>K</mml:mi></mml:msubsup><mml:msub><mml:mi>P</mml:mi><mml:mi mathvariant="italic">mk</mml:mi></mml:msub><mml:msub><mml:mi>S</mml:mi><mml:mi mathvariant="italic">kn</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>
</p>
      <p>Let us now consider that all genes with the number of mutations of each mutation type in tumor <italic toggle="yes">n</italic> can be calculated in matrix <mml:math id="jats-math-18" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="bold">Γ</mml:mi></mml:mrow></mml:mrow></mml:math> that designed as following:<disp-formula id="cam44717-disp-0005"><mml:math id="jats-math-19" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="bold">Γ</mml:mi><mml:mo linebreak="goodbreak">=</mml:mo><mml:mfenced close="]" open="["><mml:mtable columnalign="center"><mml:mtr><mml:mtd><mml:msub><mml:msup><mml:mi>N</mml:mi><mml:mi>n</mml:mi></mml:msup><mml:mn>11</mml:mn></mml:msub></mml:mtd><mml:mtd><mml:mo>⋯</mml:mo></mml:mtd><mml:mtd><mml:mo>⋯</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>⋮</mml:mo></mml:mtd><mml:mtd><mml:mo>⋱</mml:mo></mml:mtd><mml:mtd><mml:mo>⋮</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>⋯</mml:mo></mml:mtd><mml:mtd><mml:mo>⋯</mml:mo></mml:mtd><mml:mtd><mml:msub><mml:msup><mml:mi>N</mml:mi><mml:mi>n</mml:mi></mml:msup><mml:mi mathvariant="italic">MG</mml:mi></mml:msub></mml:mtd></mml:mtr></mml:mtable></mml:mfenced><mml:mo>,</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>where the <mml:math id="jats-math-20" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>G</mml:mi></mml:mrow></mml:mrow></mml:math> represents the number of gene lists in the data set. Here, we define <mml:math id="jats-math-21" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>ρ</mml:mi><mml:mi mathvariant="italic">mg</mml:mi><mml:mi>n</mml:mi></mml:msubsup></mml:mrow></mml:mrow></mml:math> as the impact factor of mutations of category <italic toggle="yes">m</italic> in sample <italic toggle="yes">n</italic> due to a gene <italic toggle="yes">g</italic>, and it can be calculated by the following formula:<disp-formula id="cam44717-disp-0006"><mml:math id="jats-math-22" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>ρ</mml:mi><mml:mi mathvariant="italic">mg</mml:mi><mml:mi>n</mml:mi></mml:msubsup><mml:mo linebreak="goodbreak">=</mml:mo><mml:mfrac><mml:msubsup><mml:mi>N</mml:mi><mml:mi mathvariant="italic">mg</mml:mi><mml:mi>n</mml:mi></mml:msubsup><mml:mrow><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>G</mml:mi></mml:msubsup><mml:msubsup><mml:mi>N</mml:mi><mml:mi mathvariant="italic">mi</mml:mi><mml:mi>n</mml:mi></mml:msubsup></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>
</p>
      <p>Then the contribution of mutational signature <italic toggle="yes">s</italic> to mutations of category <italic toggle="yes">m</italic> in a gene <italic toggle="yes">g</italic> in tumor <italic toggle="yes">n</italic> can be estimated as:<disp-formula id="cam44717-disp-0007"><inline-graphic xlink:href="CAM4-11-4053-e004.jpg"/></disp-formula>
</p>
      <p>Therefore, we consider that the cumulative abundance of a gene <italic toggle="yes">g</italic> that is attributed to mutational signature <italic toggle="yes">s</italic> in tumor <italic toggle="yes">n</italic> can be estimated as follows:<disp-formula id="cam44717-disp-0008"><mml:math id="jats-math-24" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>α</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>g</mml:mi></mml:mrow></mml:mfenced><mml:mo linebreak="goodbreak">=</mml:mo><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>M</mml:mi></mml:msubsup><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:msubsup><mml:mi>θ</mml:mi><mml:mfenced close=")" open="("><mml:mi mathvariant="italic">sg</mml:mi><mml:mo>,</mml:mo><mml:mspace width="0.1pc"/><mml:mi mathvariant="italic">mn</mml:mi></mml:mfenced><mml:mo>.</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>
</p>
      <p>On the other hand, considering the influence of gene length, we also define the relative abundance of a gene <italic toggle="yes">g</italic> that is attributed to mutational signature <italic toggle="yes">s</italic> in tumor <italic toggle="yes">n</italic>, which can be calculated as follows:<disp-formula id="cam44717-disp-0009"><mml:math id="jats-math-25" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>η</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>g</mml:mi></mml:mrow></mml:mfenced><mml:mo linebreak="goodbreak">=</mml:mo><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>M</mml:mi></mml:msubsup><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:msubsup><mml:mi>γ</mml:mi><mml:mfenced close=")" open="("><mml:mi>sg</mml:mi><mml:mo>,</mml:mo><mml:mspace width="0.1pc"/><mml:mi mathvariant="italic">mn</mml:mi></mml:mfenced><mml:mo>.</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>where <italic toggle="yes">l</italic>
<sub><italic toggle="yes">g</italic></sub> represents the length of the gene <italic toggle="yes">g</italic>. And <mml:math id="jats-math-26" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>γ</mml:mi><mml:mfenced close=")" open="("><mml:mi mathvariant="italic">sg</mml:mi><mml:mo>,</mml:mo><mml:mspace width="0.1pc"/><mml:mi mathvariant="italic">mn</mml:mi></mml:mfenced></mml:mrow></mml:mrow></mml:math> is on behalf of the relative abundance of mutational signature <italic toggle="yes">s</italic> to mutations of category <italic toggle="yes">m</italic> in a gene <italic toggle="yes">g</italic> in tumor <italic toggle="yes">n</italic> can be estimated as:<disp-formula id="cam44717-disp-0010"><inline-graphic xlink:href="CAM4-11-4053-e014.jpg"/></disp-formula>where the <mml:math id="jats-math-28" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:msup><mml:msup><mml:mi>ρ</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mi>n</mml:mi></mml:msup><mml:mi mathvariant="italic">mg</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math> can be calculated by the following formula:<disp-formula id="cam44717-disp-0011"><mml:math id="jats-math-29" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:msup><mml:msup><mml:mi>ρ</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mi>n</mml:mi></mml:msup><mml:mi mathvariant="italic">mg</mml:mi></mml:msub><mml:mo linebreak="goodbreak">=</mml:mo><mml:mfrac><mml:mfrac><mml:msubsup><mml:mi>N</mml:mi><mml:mi mathvariant="italic">mg</mml:mi><mml:mi>n</mml:mi></mml:msubsup><mml:msub><mml:mi>l</mml:mi><mml:mi>g</mml:mi></mml:msub></mml:mfrac><mml:mrow><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>G</mml:mi></mml:msubsup><mml:mfrac><mml:msubsup><mml:mi>N</mml:mi><mml:mi mathvariant="italic">mi</mml:mi><mml:mi>n</mml:mi></mml:msubsup><mml:msub><mml:mi>l</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfrac></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>
</p>
      <p>Finally, based on the research results of the previous workers,<xref rid="cam44717-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="cam44717-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="cam44717-bib-0021" ref-type="bibr"><sup>21</sup></xref>, <xref rid="cam44717-bib-0037" ref-type="bibr"><sup>37</sup></xref> we integrated and optimized some methods to evaluate the association between gene mutation and mutational signatures. We hope that through these methods, we can provide a convenient program interface for researchers, and further provide new ideas for the study of tumor mechanism.</p>
    </sec>
    <sec id="cam44717-sec-0013">
      <label>2.7</label>
      <title>Prognostic analysis</title>
      <p>Kaplan–Meier survival analysis and Cox proportional hazards model were used to analyze an association between cancer‐related genes and prognosis. Kaplan–Meier survival and Cox regression analyses were carried out with the <italic toggle="yes">R</italic> survival package (2.40–1). <italic toggle="yes">p</italic>‐value less than 0.05 was considered to be statistically significant.</p>
    </sec>
    <sec id="cam44717-sec-0014">
      <label>2.8</label>
      <title>Image analysis</title>
      <p>To obtain some favorable statistical information, and even get some prognosis evaluation or medication guidance, which is helpful for clinical treatment, we designed a way to transform CCA of gene in each mutational signature into intuitive image information. The detailed operations are as follows: (1) we can sequence these genes through some potential relationships, such as similarity, pathway, or clinical association; (2) according to these CCA matrix results, some standard visual impact images are generated; and (3) we can apply these images to deep learning model, combined with clinical information for analysis and mining.</p>
      <p>In this work, we use “hclust” clustering to get the gene sequence based on the CCA matrix of genes. From our mutation data set, we will screen out the list of all non‐silent mutation genes in the existing mutation set and do intersection processing with 717 genes. The intersecting gene set is the final data information transformed into image. We organize the data set into a <italic toggle="yes">N</italic> × <italic toggle="yes">N</italic> matrix (where <mml:math id="jats-math-30" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:msqrt><mml:mrow><mml:mtext>Number</mml:mtext><mml:mspace width="0.3em"/><mml:mtext>of</mml:mtext><mml:mspace width="0.3em"/><mml:mtext>intersecting</mml:mtext><mml:mspace width="0.3em"/><mml:mtext>genes</mml:mtext></mml:mrow></mml:msqrt></mml:mrow></mml:mrow></mml:math>). In this paper, we arrange the genes from top to bottom with the aim of obtaining the effect picture of gene mutation. To study the effect of CCA changes in each mutational signature on the prognosis, the deep learning framework PyTorch<xref rid="cam44717-bib-0038" ref-type="bibr"><sup>38</sup></xref> was performed to train some publicly available models, such as ResNet<xref rid="cam44717-bib-0039" ref-type="bibr"><sup>39</sup></xref> (ResNet50, ResNet101), DenseNet<xref rid="cam44717-bib-0040" ref-type="bibr"><sup>40</sup></xref>, <xref rid="cam44717-bib-0041" ref-type="bibr"><sup>41</sup></xref> (DenseNet‐121, DenseNet‐161), Inception‐V4<xref rid="cam44717-bib-0042" ref-type="bibr"><sup>42</sup></xref> and MoblieNet‐V2,<xref rid="cam44717-bib-0043" ref-type="bibr"><sup>43</sup></xref> V3.<xref rid="cam44717-bib-0044" ref-type="bibr"><sup>44</sup></xref> First of all, we uniformly limit the pixels of the picture to 500*500.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="cam44717-sec-0015">
    <label>3</label>
    <title>RESULTS</title>
    <sec id="cam44717-sec-0016">
      <label>3.1</label>
      <title>Framework analysis of <styled-content style="fixed-case" toggle="no">RNMF</styled-content>
</title>
      <p>Optimizing and improving the derivation of mutational signatures can not only rediscover some known features, but also produce new discoveries that were previously masked by technical and biological confusions. Here, we designed a simple and convenient process framework by R language (Figure <xref rid="cam44717-fig-0001" ref-type="fig">1</xref>) and developed a novel R package called <italic toggle="yes">RNMF</italic> (<ext-link xlink:href="https://github.com/zhenzhang-li/RNMF" ext-link-type="uri">https://github.com/zhenzhang‐li/RNMF</ext-link>). The package <italic toggle="yes">RNMF</italic> can directly analyze the mutation data set which exist in the form of MAF or VCF format files, rapidly obtain the number of specific mutation types in each sample and then resolve the mutational signatures. This software can achieve 7 kinds of outstanding functions: (1) the mutation rate per M shown in LEGO graph; (2) rapidly extraction of mutational signatures; (3) accurately evaluating the contribution of each sample to the known mutation profile; (4) deeply studying on the similarity of mutational signatures and displaying the heat‐map; (5) calculating the CCA matrix of genes; (6) studying the relationship between mutational signatures and genes; and (7) studying on the relationship between hotspot mutation of driving factors and mutational signatures.</p>
      <p>One outstanding function of <italic toggle="yes">RNMF</italic> is defined as <italic toggle="yes">SigsInput,</italic> which is suitable for large or most small data sets, providing analysis interfaces for different types of genomic DNA changes, such as SBS, DBS, small ID. To prove high performance of our designed <italic toggle="yes">RNMF</italic>, the mutation data sets of 1073 ESCC samples from Asia (including 508 WGS data) are analyzed thoroughly. These mutation data were extracted from the appendix of published articles (Table <xref rid="cam44717-supitem-0010" ref-type="supplementary-material">S1</xref>), and were annotated by <italic toggle="yes">Oncotator</italic>.<xref rid="cam44717-bib-0045" ref-type="bibr"><sup>45</sup></xref> As shown in Figure <xref rid="cam44717-fig-0001" ref-type="fig">1</xref>, by extracting the mutational signatures with the designed <italic toggle="yes">denovoNMF</italic> function, the evaluation results exhibits the change of silhouette coefficient and error gradient.</p>
      <p>In the Figure <xref rid="cam44717-fig-0001" ref-type="fig">1</xref>, an application interface “<italic toggle="yes">InverseNMF</italic>” can calculate the fraction of one sample which is contributed to each provided mutational signatures. By our designed <italic toggle="yes">RNMF</italic>, we analyzed the contribution scores of these coding region mutations to each mutational signature which are gotten from the COSMIC Mutational Signatures (v2.0 ‐ March 2015). The results are highly consistent with the analysis ones of the known “<italic toggle="yes">MutationalPatterns</italic>”<xref rid="cam44717-bib-0020" ref-type="bibr"><sup>20</sup></xref> and “<italic toggle="yes">deconstructSigs</italic>” software,<xref rid="cam44717-bib-0037" ref-type="bibr"><sup>37</sup></xref> as shown in Figure <xref rid="cam44717-supitem-0003" ref-type="supplementary-material">S3</xref>A. It is worth noting that operating speed of “<italic toggle="yes">InverseNMF</italic>” rivals to that of “<italic toggle="yes">MutationalPatterns</italic>” software, however, is 12 times faster than that of “<italic toggle="yes">deconstructSigs</italic>” software (Figure <xref rid="cam44717-supitem-0003" ref-type="supplementary-material">S3</xref>B). To go insight into the inner link between mutational signatures and gene mutations, a series of powerful functions are designed according to the the CCA calculation model of gene, such as “<italic toggle="yes">cumulativeCA,</italic>” “<italic toggle="yes">genePerMutSigs,</italic>” “<italic toggle="yes">samFisherSigs,</italic>” “<italic toggle="yes">samPerMutSigs,</italic>” and “<italic toggle="yes">eachMutationCA</italic>.” The detailed analysis description will be provided in the example of our designed <italic toggle="yes">RNMF</italic>.</p>
      <p>According to the previous reports,<xref rid="cam44717-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="cam44717-bib-0024" ref-type="bibr"><sup>24</sup></xref>, <xref rid="cam44717-bib-0033" ref-type="bibr"><sup>33</sup></xref> we define that if the CCA of a gene in a sample to a signature is less than 6%, the gene in the sample has little effect on the signature. Next, we combined non‐silent mutations, sorted gene list and clinical grouping information to obtain gene mutation image sets of samples under different mutational signatures based on gene CCA matrix. Then, deep learning method was used to process these image information for hierarchical learning, which could obtain some biological cognition, so that we could deeply understand some useful information for adjuvant therapy, such as prognosis evaluation, efficacy evaluation, medication guidance and so on (Figure <xref rid="cam44717-fig-0001" ref-type="fig">1</xref>).</p>
      <p>In a word, as a versatile R package, <italic toggle="yes">RNMF</italic> can realize parallel operation that helps to study and evaluate the mutational processes during tumor development. Thus, molecular analysis can be performed based on extracted mutational signatures, further revealing the molecular mechanisms and optimizing the diagnosis and treatment decisions.</p>
    </sec>
    <sec id="cam44717-sec-0017">
      <label>3.2</label>
      <title>Identifying mutational signatures via <styled-content style="fixed-case" toggle="no">RNMF</styled-content>
</title>
      <p>The incidence and mortality of esophageal cancer have always been relatively high, as in China, for example, among which ESCC accounts for 90% of esophageal cancer.<xref rid="cam44717-bib-0046" ref-type="bibr"><sup>46</sup></xref> A previous study has provided a large genome‐wide sequencing cohort of Chinese ESCC population.<xref rid="cam44717-bib-0047" ref-type="bibr"><sup>47</sup></xref> To demonstrate the role of <italic toggle="yes">RNMF</italic> in the extraction of mutational singatures, our designed <italic toggle="yes">RNMF</italic> is used to systematically analyze the mutation data set (single base mutations and INDEL mutations) of this cohort data. In the overall single base mutation pattern of ESCC, it is mainly C&gt;T and C&gt;G mutation, followed by C&gt;A mutation, accounting for 34.9%, 18.81% and 15.94%, respectively (Figure <xref rid="cam44717-supitem-0004" ref-type="supplementary-material">S4</xref>). Besides the insertion of a zero‐length 1‐bp T base homologous sequence, most other types of deficient incongruities are characterized by long (≥5) thymine mononucleotide repeats.</p>
      <p>In this cohort, the <italic toggle="yes">RNMF</italic> successfully identified 12 single base substitutions signatures, named SBS1, SBS2, …, SBS12, respectively, which is compared with the COSMIC signatures (<ext-link xlink:href="https://cancer.sanger.ac.uk/signatures;" ext-link-type="uri">https://cancer.sanger.ac.uk/signatures;</ext-link> Figure <xref rid="cam44717-fig-0002" ref-type="fig">2</xref>, Figure <xref rid="cam44717-supitem-0002" ref-type="supplementary-material">S2</xref>A, Table <xref rid="cam44717-supitem-0011" ref-type="supplementary-material">S2</xref>A,B). Mutational Signatures description are represented in Table <xref rid="cam44717-tbl-0001" ref-type="table">1</xref>.</p>
      <fig position="float" fig-type="FIGURE" id="cam44717-fig-0002">
        <label>FIGURE 2</label>
        <caption>
          <p>SBS signatures extracted from 508 Chinese patients with esophageal squamous cell carcinoma. The left side of the picture shows the classifications of 96 mutation types. Each color is used to illustrate the positions of each mutation subtype on each plot. The right side of the picture shows heatmap of the cosine similarity between mutational signatures and COSMIC Mutational Signatures (v3.1 ‐ June 2020). The shade of color corresponds to different cosine similarity scores. The single‐base substitution signatures with cosine similarity score no less than 0.6 are shown at the bottom of the figure, and the most similar one is highlighted in red</p>
        </caption>
        <graphic xlink:href="CAM4-11-4053-g007" position="anchor" id="jats-graphic-5"/>
      </fig>
      <table-wrap position="float" id="cam44717-tbl-0001" content-type="TABLE">
        <label>TABLE 1</label>
        <caption>
          <p>Mutational Signatures description</p>
        </caption>
        <table frame="hsides" rules="groups">
          <col align="left" span="1"/>
          <col align="center" span="1"/>
          <col align="center" span="1"/>
          <col align="center" span="1"/>
          <col align="left" span="1"/>
          <thead valign="bottom">
            <tr style="border-bottom:solid 1px #000000">
              <th align="left" valign="bottom" rowspan="1" colspan="1">Original name</th>
              <th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Matching COSMIC</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Cosine similarity</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Redefine name</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Comments</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" colspan="5" valign="top" rowspan="1">SBS Signatures</td>
            </tr>
            <tr>
              <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">SBS1</td>
              <td align="center" valign="top" rowspan="1" colspan="1">SBS3</td>
              <td align="center" valign="top" rowspan="1" colspan="1">0.83</td>
              <td align="center" valign="top" rowspan="1" colspan="1">
                <bold>SBS3*</bold>
              </td>
              <td align="left" valign="top" rowspan="1" colspan="1">
                <p><italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> mutations;</p>
                <p><italic toggle="yes">BRCA1</italic> promoter methylation;</p>
                <p>homologous recombination deficiency</p>
              </td>
            </tr>
            <tr>
              <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">SBS2</td>
              <td align="center" valign="top" rowspan="1" colspan="1">SBS16</td>
              <td align="center" valign="top" rowspan="1" colspan="1">0.84</td>
              <td align="center" valign="top" rowspan="1" colspan="1">
                <bold>SBS16*</bold>
              </td>
              <td align="left" valign="top" rowspan="1" colspan="1">Alcoholic consumption</td>
            </tr>
            <tr>
              <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">SBS3</td>
              <td align="center" valign="top" rowspan="1" colspan="1">SBS18</td>
              <td align="center" valign="top" rowspan="1" colspan="1">0.98</td>
              <td align="center" valign="top" rowspan="1" colspan="1">
                <bold>SBS18*</bold>
              </td>
              <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">CDH1</italic> mutations<xref rid="cam44717-bib-0021" ref-type="bibr"><sup>21</sup></xref>; <italic toggle="yes">MUTYH</italic> mutations</td>
            </tr>
            <tr>
              <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">SBS5</td>
              <td align="center" valign="top" rowspan="1" colspan="1">SBS33</td>
              <td align="center" valign="top" rowspan="1" colspan="1">0.98</td>
              <td align="center" valign="top" rowspan="1" colspan="1">
                <bold>SBS33*</bold>
              </td>
              <td align="left" valign="top" rowspan="1" colspan="1">Unknown</td>
            </tr>
            <tr>
              <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">SBS6</td>
              <td align="center" valign="top" rowspan="1" colspan="1">SBS13*</td>
              <td align="center" valign="top" rowspan="1" colspan="1">0.98</td>
              <td align="center" valign="top" rowspan="1" colspan="1">
                <bold>SBS13*</bold>
              </td>
              <td align="left" valign="top" rowspan="1" colspan="1">ABOPEC; <italic toggle="yes">PIK3CA</italic> mutation [This article]</td>
            </tr>
            <tr>
              <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">SBS7</td>
              <td align="center" valign="top" rowspan="1" colspan="1">SBS2*</td>
              <td align="center" valign="top" rowspan="1" colspan="1">1.00</td>
              <td align="center" valign="top" rowspan="1" colspan="1">
                <bold>SBS2*</bold>
              </td>
              <td align="left" valign="top" rowspan="1" colspan="1">ABOPEC; <italic toggle="yes">PIK3CA</italic> mutation [This article]</td>
            </tr>
            <tr>
              <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">SBS8</td>
              <td align="center" valign="top" rowspan="1" colspan="1">SBS5</td>
              <td align="center" valign="top" rowspan="1" colspan="1">0.90</td>
              <td align="center" valign="top" rowspan="1" colspan="1">
                <bold>SBS5*</bold>
              </td>
              <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">ERCC2</italic> mutations; tobacco smoking</td>
            </tr>
            <tr>
              <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">SBS9</td>
              <td align="center" valign="top" rowspan="1" colspan="1">SBS1</td>
              <td align="center" valign="top" rowspan="1" colspan="1">0.96</td>
              <td align="center" valign="top" rowspan="1" colspan="1">
                <bold>SBS1*</bold>
              </td>
              <td align="left" valign="top" rowspan="1" colspan="1">Age; <italic toggle="yes">TP53</italic> mutation [This article]</td>
            </tr>
            <tr>
              <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">SBS10</td>
              <td align="center" valign="top" rowspan="1" colspan="1">SBS17b</td>
              <td align="center" valign="top" rowspan="1" colspan="1">0.90</td>
              <td align="center" valign="top" rowspan="1" colspan="1">
                <bold>SBS17b*</bold>
              </td>
              <td align="left" valign="top" rowspan="1" colspan="1">Gastric acid reflux; fluorouracil (5FU) chemotherapy treatment</td>
            </tr>
            <tr>
              <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">SBS11</td>
              <td align="center" valign="top" rowspan="1" colspan="1">SBS22</td>
              <td align="center" valign="top" rowspan="1" colspan="1">0.98</td>
              <td align="center" valign="top" rowspan="1" colspan="1">
                <bold>SBS22*</bold>
              </td>
              <td align="left" valign="top" rowspan="1" colspan="1">Aristolochic acid</td>
            </tr>
            <tr>
              <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">SBS12</td>
              <td align="center" valign="top" rowspan="1" colspan="1">SBS15</td>
              <td align="center" valign="top" rowspan="1" colspan="1">0.95</td>
              <td align="center" valign="top" rowspan="1" colspan="1">
                <bold>SBS15*</bold>
              </td>
              <td align="left" valign="top" rowspan="1" colspan="1">DNA mismatch repair defificiency</td>
            </tr>
            <tr>
              <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">SBS4</td>
              <td align="center" valign="top" rowspan="1" colspan="1">‐</td>
              <td align="center" valign="top" rowspan="1" colspan="1">‐</td>
              <td align="center" valign="top" rowspan="1" colspan="1">
                <bold>New</bold>
              </td>
              <td align="left" valign="top" rowspan="1" colspan="1">Unknown</td>
            </tr>
            <tr>
              <td align="left" colspan="5" valign="top" rowspan="1">ID Signatures</td>
            </tr>
            <tr>
              <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ID3</td>
              <td align="center" valign="top" rowspan="1" colspan="1">ID6</td>
              <td align="center" valign="top" rowspan="1" colspan="1">0.94</td>
              <td align="center" valign="top" rowspan="1" colspan="1">
                <bold>ID6*</bold>
              </td>
              <td align="left" valign="top" rowspan="1" colspan="1">Homologous recombination‐based repair</td>
            </tr>
            <tr>
              <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ID6</td>
              <td align="center" valign="top" rowspan="1" colspan="1">ID2</td>
              <td align="center" valign="top" rowspan="1" colspan="1">0.99</td>
              <td align="center" valign="top" rowspan="1" colspan="1">
                <bold>ID2*</bold>
              </td>
              <td align="left" valign="top" rowspan="1" colspan="1">DNA mismatch repair defificiency</td>
            </tr>
            <tr>
              <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ID2</td>
              <td align="center" valign="top" rowspan="1" colspan="1">ID14</td>
              <td align="center" valign="top" rowspan="1" colspan="1">0.88</td>
              <td align="center" valign="top" rowspan="1" colspan="1">
                <bold>ID14*</bold>
              </td>
              <td align="left" valign="top" rowspan="1" colspan="1">Unknown</td>
            </tr>
            <tr>
              <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ID1,ID4,ID5, ID7‐ID9</td>
              <td align="center" valign="top" rowspan="1" colspan="1">‐</td>
              <td align="center" valign="top" rowspan="1" colspan="1">‐</td>
              <td align="center" valign="top" rowspan="1" colspan="1">
                <bold>New1‐New6</bold>
              </td>
              <td align="left" valign="top" rowspan="1" colspan="1">Unknown</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot id="cam44717-ntgp-0001">
          <fn id="cam44717-note-0001">
            <p><italic toggle="yes">Note</italic>: “‐” represents there is no match feature or the similarity is generally very low.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>To verify the accuracy of the above results, the known <italic toggle="yes">SigProfilerExtractor</italic> software<xref rid="cam44717-bib-0023" ref-type="bibr"><sup>23</sup></xref> is also used to analyze SBS signatures, and extract 13 features (Figures <xref rid="cam44717-supitem-0002" ref-type="supplementary-material">S2</xref>B, <xref rid="cam44717-supitem-0005" ref-type="supplementary-material">S5</xref>). By further making a similarity comparison, we found that whether using V2 or V3 version of COSMIC signature, it shows strong consistency (Figure <xref rid="cam44717-fig-0002" ref-type="fig">2</xref>, Figure <xref rid="cam44717-supitem-0001" ref-type="supplementary-material">S1</xref>A,B). Moveover, the results were basically consistent between <italic toggle="yes">RNMF</italic> and <italic toggle="yes">SigProfilerExtractor</italic> (Figure <xref rid="cam44717-supitem-0001" ref-type="supplementary-material">S1</xref>C). Thus, these results enough show the validity of the <italic toggle="yes">RNMF</italic>. In addition, we also extract ID signature. Nine ID signatures were prominent (Figure <xref rid="cam44717-supitem-0002" ref-type="supplementary-material">S2</xref>C, Figure <xref rid="cam44717-fig-0003" ref-type="fig">3</xref>, Table <xref rid="cam44717-supitem-0011" ref-type="supplementary-material">S2</xref>C‐D), and three of them have been previously reported, including two with known mutational processes.<xref rid="cam44717-bib-0023" ref-type="bibr"><sup>23</sup></xref> Mutational Signatures description are represented in Table <xref rid="cam44717-tbl-0001" ref-type="table">1</xref>.</p>
      <fig position="float" fig-type="FIGURE" id="cam44717-fig-0003">
        <label>FIGURE 3</label>
        <caption>
          <p>Insertion and deletion mutation (ID) signatures extracted from 508 Chinese patients with esophageal squamous cell carcinoma. The left side of the picture shows the classifications of 83 mutation types. Each color is used to illustrate the positions of each mutation subtype on each plot. The right side of the picture shows heatmap of the cosine similarity between mutational signatures and COSMIC Mutational Signatures (v3.1 ‐ June 2020). The shade of color corresponds to different cosine similarity scores. The ID signatures with cosine similarity score no less than 0.6 are shown at the bottom of the figure, and the most similar one is highlighted in red. At the bottom of the figure, the specific information of 83 mutation types is given, and the colors correspond to the columns in the left image one by one</p>
        </caption>
        <graphic xlink:href="CAM4-11-4053-g008" position="anchor" id="jats-graphic-7"/>
      </fig>
    </sec>
    <sec id="cam44717-sec-0018">
      <label>3.3</label>
      <title>Estimation of sample contribution under known mutational signatures by <styled-content style="fixed-case" toggle="no">RNMF</styled-content>
</title>
      <p>To verify the practicability of the functions in our framework, the contribution of samples was analyzed in the known mutational signatures. We collected a total of 115,130 somatic mutations from exon region of 1073 ESCC samples, including 16 of them were hyper‐mutated with mutation count more than 500 (Figure <xref rid="cam44717-fig-0004" ref-type="fig">4A</xref>, Table <xref rid="cam44717-supitem-0012" ref-type="supplementary-material">S3</xref>). Comparing with 508‐WGS cohort, we found that the overall proportion of C&gt;T mutations increased in the exon region, among which *[C&gt;T]G context changed greatly (Figure <xref rid="cam44717-supitem-0006" ref-type="supplementary-material">S6</xref>A). However, the single base mutations in the exon region were mainly C&gt;T (48.19%) and C&gt;G (18.2%), followed by C&gt;A (13.8%), indicating that the mutation pattern of exon region was similar to that of whole genome.</p>
      <fig position="float" fig-type="FIGURE" id="cam44717-fig-0004">
        <label>FIGURE 4</label>
        <caption>
          <p>Mutational signatures reconstruction from 1073 esophageal squamous cell carcinoma (ESCC) cases. (A) The top figure of the graph shows the statistics of hypermutation. Using Ckmeans.1d.dp to cluster the number of mutations of 1073 ESCC samples, 16 hypermutated samples (red dots) and 1057 regular tumors (yellow and gray dots) are found. The bottom figure of the graph shows the proportion of six mutation types of 1073 ESCC samples with point mutation, and the X‐axis represents the sample, Each sample has a single column, and each color represents a mutation type. (B) Based on the background mutation contribution probability of COSMIC Mutational Signatures (v3.2 ‐ March 2021), each color represents a mutational signature, the length of each column represents the contribution ratio of mutation to the signature, the red mark represents the signature most similar to the 12 mutational signature, and the green arrow and green font indicate that this signature is very similar to the 12 mutational signature. Yellow means that the similarity between the signature and 12 mutational signatures is very low. (C) Percentage of ESCC tumors in each signature was displayed (top) and mutation rate for each signature in the relevant samples (bottom). If the contribution of a sample assigned to one signature is not less than 20%, we would consider that this signature is present in the sample. (D) The association between mutational activity of single‐base substitution (SBS) signatures (SBS5* and SBS16*) and alcohol consumption. The violin compared the difference between drinking and non drinking groups from the mutation count and the contribution of samples to the signatures, and the significant p‐value was statistically analyzed by Student's <italic toggle="yes">t</italic>‐test with two‐sided. (E) The heatmap shows the distribution of cumulative contribution abundance of cancer‐related genes from the COSMIC census, and the depth of color represents the degree of correlation. (F) Box plot showing that the SBS signatures were associated with cancer‐related genes mutations (including SNV and indel), where n represents the number of samples. Statistical significance was tested by rank sum test with two sided. (G) The contribution of non‐silent mutations in the coding regions of 40 cancer‐related genes is statistically analyzed. Each color represents a class of mutation feature map, and the pie chart shows the proportion of each feature. In the figure, the top figure shows the total CCA of each gene in 1073 samples, while the bottom figure shows the proportion of each mutational signature, and a column represents a gene. Gene selection rules: the number of non‐silent mutations is more than 30 and belongs to cancer‐related genes from the COSMIC census</p>
        </caption>
        <graphic xlink:href="CAM4-11-4053-g002" position="anchor" id="jats-graphic-9"/>
      </fig>
      <p>To better explore and analyze the potential features of exon regions, we used Single Base Substitution (SBS) Signatures (v3.2 ‐ March 2021 and v2.0 ‐ March 2015) from COSMIC database as the provided mutational signatures to obtain the number of contribution mutations of samples in each signature. We analyzed three single base mutation data sets: 508‐WGS cohort (WGS508), exon region of 508‐WGS cohort (EXON508) and exon region of 1072 samples (EXON1073). For the 12 feature maps extracting from WGS data, the trends of WGS508, EXON508 and EXON1073 are basically the same under the same background (Figure <xref rid="cam44717-fig-0004" ref-type="fig">4B</xref>, Figure <xref rid="cam44717-supitem-0006" ref-type="supplementary-material">S6</xref>B). However, the results of WGS508 revealed that the signature, which accounted for a large proportion, may not exist in the list of 12 decomposed signatures, and these signatures either have high similarity or low similarity related to those 12 signatures. What's more, the results of WGS508 showed that compared with the results of different versions of COSMIC Mutational Signatures, we found that with the increase of features background analysis, high similar or low similarity signatures with high proportion will be produced, indicating that adding background features may introduce some unimportant or similar features to share the load weight (Figure <xref rid="cam44717-fig-0004" ref-type="fig">4B</xref>, Figure <xref rid="cam44717-supitem-0006" ref-type="supplementary-material">S6</xref>B). Meanwhile, under the same background, the results of EXON508 and EXON1073 showed that the number of samples play little role in the proportion of signatures (Figure <xref rid="cam44717-fig-0004" ref-type="fig">4B</xref>, Figure <xref rid="cam44717-supitem-0006" ref-type="supplementary-material">S6</xref>B). In addition, previous reports<xref rid="cam44717-bib-0024" ref-type="bibr"><sup>24</sup></xref>, <xref rid="cam44717-bib-0047" ref-type="bibr"><sup>47</sup></xref> showed that each kind of cancer has its own important characteristics. Of which the number or type of signatures is usually different. These different main signatures play a leading role in the occurrence and development of different tumor types.</p>
      <p>In this paper, by combining the results of our analysis and the reported results (Figure <xref rid="cam44717-supitem-0005" ref-type="supplementary-material">S5</xref>), we strongly believe that 12 stable SBS signatures, which is extracted from the 508‐WGS cohort, should be the outstanding features of ESCC, which are considered as the leading mutation patterns in the occurrence and development of this tumor. Therefore, these 12 features were selected as background walls for the analysis of ESCC tumors (Table <xref rid="cam44717-supitem-0013" ref-type="supplementary-material">S4</xref>). We found that the signatures SBS1*, SBS2*, SBS5*, SBS13* and SBS15* were effective in most samples containing more somatic mutations, which are considered as ubiquitous signatures (Figure <xref rid="cam44717-fig-0004" ref-type="fig">4C</xref>, Figure <xref rid="cam44717-supitem-0006" ref-type="supplementary-material">S6</xref>C). By contrast, signatures SBS3*, SBS16*, SBS17b*, SBS18*, SBS22*, New, and SBS33* were sporadic signatures which existed in rare samples (≤8% of cases). Interestingly, clinical association analysis revealed that compared with non‐drinking patients, drinking patients contributed significantly more mutations to SBS5* and SBS16*, and their contribution also increased significantly, suggesting that these two SBS signatures may be related to alcohol consumption (Figure <xref rid="cam44717-fig-0004" ref-type="fig">4D</xref>).</p>
    </sec>
    <sec id="cam44717-sec-0019">
      <label>3.4</label>
      <title><styled-content style="fixed-case" toggle="no">Cumulative contribution abundance</styled-content> analysis reveals potential prognostic features and mechanisms through <styled-content style="fixed-case" toggle="no">RNMF</styled-content>
</title>
      <p>In this work, a total of 717 cancer‐related genes are screened from the COSMIC census (<ext-link xlink:href="https://cancer.sanger.ac.uk/census" ext-link-type="uri">https://cancer.sanger.ac.uk/census</ext-link>, Table <xref rid="cam44717-supitem-0014" ref-type="supplementary-material">S5</xref>) and their CCAs were calculated via <italic toggle="yes">RNMF</italic> software with a given model function named “<italic toggle="yes">cumulativeCA</italic>”. Through this program algorithm interface, CCA of a gene on a signature and CCA of a gene on a signature in a sample can be obtained. We found that these cancer‐related genes are more enriched in ubiquitous signatures, especially signatures such as SBS1*, SBS2*, and SBS13* (Figure <xref rid="cam44717-fig-0004" ref-type="fig">4E</xref>). There are differences in CCA levels of genes under different mutational signatures, which indicates that genes have their preference for mutational signatures. At the same time, survival analysis found that CCA of several genes was associated with prognosis (Figure <xref rid="cam44717-supitem-0007" ref-type="supplementary-material">S7</xref>A, Table <xref rid="cam44717-supitem-0015" ref-type="supplementary-material">S6</xref>). In addition, a multivariate Cox model was confirmed that some of them were still significant (Figure <xref rid="cam44717-supitem-0007" ref-type="supplementary-material">S7</xref>B), such as <italic toggle="yes">ARHGAP5</italic>, <italic toggle="yes">SETD2</italic>, <italic toggle="yes">RNF213</italic>, <italic toggle="yes">CDKN2A</italic>, <italic toggle="yes">NOTCH1</italic>, <italic toggle="yes">NFE2L2</italic>, and so on. Analysis of mutation characteristics showed that <italic toggle="yes">TP53</italic> mutation significantly increased exposure to SBS1*, but conversely, the contribution to SBS1* was significantly reduced in samples carrying <italic toggle="yes">RNF213</italic> mutation (Figure <xref rid="cam44717-fig-0004" ref-type="fig">4F</xref>, Figure <xref rid="cam44717-supitem-0008" ref-type="supplementary-material">S8</xref>A). Furthermore, among the <italic toggle="yes">TP53</italic> mutant samples, the contribution of the RNF213 mutant samples to SBS1* was significantly reduced(Figure <xref rid="cam44717-supitem-0008" ref-type="supplementary-material">S8</xref>A). Similarly, we found a significant increase in the contribution of APOBEC signatures (SBS2*, SBS13*) in ESCC samples with <italic toggle="yes">PIK3CA</italic> mutations, and the other three genes (<italic toggle="yes">ARHGAP5</italic>, <italic toggle="yes">SETD2</italic>, and <italic toggle="yes">UBR5</italic>) were also associated with APOBEC signature (SBS13*) (Figure <xref rid="cam44717-fig-0004" ref-type="fig">4F</xref>, Figure <xref rid="cam44717-supitem-0008" ref-type="supplementary-material">S8</xref>A). It is noted that <italic toggle="yes">NFE2L2</italic> mutation was related to SBS16*. These above results indicate that there is a potential mechanism between gene mutations and mutational signatures in the process of tumorigenesis and development. Thus, we studied 40 representative genes from 717 cancer‐related genes, which contained about 3.6% of the total number of non‐silent SNV mutations. Most of these mutations preferred the characteristic SBS1* (15%), SBS2* (11%), SBS5* (12%), SBS13* (10%), and SBS18* (12%), but were less distributed in SBS17b* (3%) (Figure <xref rid="cam44717-fig-0004" ref-type="fig">4G</xref>). We found that 66.5% of 1073 ESCC samples had non‐silent SNV of <italic toggle="yes">TP53</italic>, resulting in a highest level of CCA of <italic toggle="yes">TP53</italic> gene, and the proportion of three SBS signatures (SBS1*, SBS5*, and SBS18*) was higher, followed by SBS15*. Obviously, different genes have different ratios for different mutated traits. It attracts our attention that <italic toggle="yes">PIK3CA</italic> gene is obviously in favor of APOBEC signatures (SBS2*), which accounts for more than 50% (Figure <xref rid="cam44717-fig-0004" ref-type="fig">4G</xref>). Hence, all findings above suggest that preference of cancer‐related genes for mutational signatures can be defined by CCA, which can further expose some potential prognostic features or mechanisms.</p>
    </sec>
    <sec id="cam44717-sec-0020">
      <label>3.5</label>
      <title><styled-content style="fixed-case" toggle="no">Cumulative contribution abundance</styled-content> analysis exposing <styled-content style="fixed-case" toggle="no">APOBEC</styled-content> are closely associated with <styled-content style="fixed-case" toggle="no"><italic toggle="no">PIK3CA</italic></styled-content> helical mutation <styled-content style="fixed-case" toggle="no">E545K</styled-content>
</title>
      <p>According to the reports,<xref rid="cam44717-bib-0048" ref-type="bibr"><sup>48</sup></xref>, <xref rid="cam44717-bib-0049" ref-type="bibr"><sup>49</sup></xref>, <xref rid="cam44717-bib-0050" ref-type="bibr"><sup>50</sup></xref>
<italic toggle="yes">PIK3CA</italic> is a typical proto‐oncogene that typically harbors some hotspot mutations in tumors and is enriched in APOBEC characteristics in a variety of cancer types, especially these two most‐common and well‐studied hotspots: E542K (c.1624G&gt;A) and E545K (c.1633G&gt;A) in the helical domain. In ESCC, the results of previous studies implicitly implicated APOBEC activity as a key driver of <italic toggle="yes">PIK3CA</italic> mutagenesis.<xref rid="cam44717-bib-0050" ref-type="bibr"><sup>50</sup></xref>, <xref rid="cam44717-bib-0051" ref-type="bibr"><sup>51</sup></xref> In this cohort, we are committed to further study the potential mechanism between <italic toggle="yes">PIK3CA</italic> biological mutations and APOBEC signatures via CCA model.</p>
      <p>By the CCA enrichment analysis, it is found that tumors with non‐silent mutations in <italic toggle="yes">PIK3CA</italic> had increased activity of the signature SBS2* (ESCC1073‐EXON: 89 tumors with non‐silent <italic toggle="yes">PIK3CA</italic> mutations and a median increase CCA of 0.74 per sample; q &lt; 0.0001, <italic toggle="yes">p</italic> &lt; 0.0001; regular tumors of ESCC1073‐EXON: 88 tumors with non‐silent <italic toggle="yes">PIK3CA</italic> mutations and a median increase CCA of 0.74 per sample; q &lt; 0.0001, <italic toggle="yes">p</italic> &lt; 0.0001; WGS508‐EXON: 38 tumors with non‐silent <italic toggle="yes">PIK3CA</italic> mutations and a median increase CCA of 0.741 per sample; q &lt; 0.0001, <italic toggle="yes">p</italic> &lt; 0.0001; Figure <xref rid="cam44717-fig-0005" ref-type="fig">5A</xref>, Figure <xref rid="cam44717-supitem-0008" ref-type="supplementary-material">S8</xref>B). Analogously, those tumors with non‐silent mutations in <italic toggle="yes">PIK3CA</italic> also had increased activity of the signature SBS13* (ESCC1073‐EXON: 89 tumors with non‐silent <italic toggle="yes">PIK3CA</italic> mutations and a median increase CCA of 0.136 per sample; q &lt; 0.0001, <italic toggle="yes">p</italic> &lt; 0.0001; regular tumors of ESCC1073‐EXON: 88 tumors with non‐silent <italic toggle="yes">PIK3CA</italic> mutations and a median increase CCA of 0.1359 per sample; q &lt; 0.0001, <italic toggle="yes">p</italic> &lt; 0.0001; WGS508‐EXON: 38 tumors with non‐silent <italic toggle="yes">PIK3CA</italic> mutations and a median increase CCA of 0.133 per sample; q = 0.0008, <italic toggle="yes">p</italic> &lt; 0.0001; Figure <xref rid="cam44717-fig-0005" ref-type="fig">5b</xref>, Figure <xref rid="cam44717-supitem-0008" ref-type="supplementary-material">S8</xref>C). To further prove these connections, we performed mutational signature enrichment analyses and gained the same results (Figure <xref rid="cam44717-supitem-0008" ref-type="supplementary-material">S8</xref>B,C), providing the strongest statistical evidence for the relationship between <italic toggle="yes">PIK3CA</italic> mutation and APOBEC signatures activity in ESCC. Together, these results further strongly suggest that, although APOBEC signatures activity are present in all tumors, somatic <italic toggle="yes">PIK3CA</italic> mutations are associated with a significant increase in APOBEC signatures activity.</p>
      <fig position="float" fig-type="FIGURE" id="cam44717-fig-0005">
        <label>FIGURE 5</label>
        <caption>
          <p>Cumulative contribution abundance (CCA) enrichment analysis identifies an association between somatic <italic toggle="yes">PIK3CA</italic> mutations and activity of SBS2* or SNS13* in esophageal squamous cell carcinoma (ESCC). (A‐B) Here, we use two data sets: exon regions of 1073 and 508 ESCC cases. First, the median CCA of each gene in the current signature is calculated, and then the contribution importance of each gene is calculated by PERMUTATION test to study the association between gene and signature. The regular patterns in the figure represent the samples with non hypermutated. For genes mutated in &gt;5% of samples, the CCA of genes attributed to SBS2* or SBS13* was compared in tumors with wild‐type versus mutated copies of the gene. Genes with FDR q &lt; 0.1 are highlighted in red. (C) Mutation trend and hotspot analysis of <italic toggle="yes">PIK3CA</italic> non‐silent mutations: the pie chart on the top left shows the proportion of six mutation types, and the pie chart on the top right shows the proportion of coding protein, with the name of the protein that accounts for a large proportion. Each color in the figure below represents a mutational signature, and the statistical proportion of the contribution of six mutation types to each mutation signature is on the left, a column represents a mutation type; The figure on the right shows the contribution abundance of classical hotspot mutant protein to each signature, and a column represents a classical mutant protein. (D‐E) The violin diagram shows the difference of contribution to SBS2* and SBS13* between the samples with <italic toggle="yes">PIK3CA</italic> hotspot mutation and other types of samples, whereas (f‐g) shows the difference of contribution abundance between the samples with <italic toggle="yes">PIK3CA</italic> non‐silent mutations (E545K and E542K) and other samples. The Wilcoxon rank sum test with two‐sided is used here, * represents (0.01 ≤ <italic toggle="yes">p</italic> &lt; 0.05), * * (0.001 ≤ <italic toggle="yes">p</italic> &lt; 0.01), ***represents (<italic toggle="yes">p</italic> &lt; 0.001), and ns represents (<italic toggle="yes">p</italic> ≥ 0.05)</p>
        </caption>
        <graphic xlink:href="CAM4-11-4053-g003" position="anchor" id="jats-graphic-11"/>
      </fig>
      <p>We also dissect the mutation spectrum of <italic toggle="yes">PIK3CA</italic> non‐silent mutations, revealing the underlying mechanism of during mutation processing. In our series, 65.22% of <italic toggle="yes">PIK3CA</italic> non‐silent mutations were C&gt;T substitution, and those mutations were frequent presenters that mostly contributed to APOBEC signatures (SBS2* and SBS13*) with highest percentage (Figure <xref rid="cam44717-fig-0005" ref-type="fig">5C</xref>). Simultaneously, we investigated the <italic toggle="yes">PIK3CA</italic> helical (E545K: 36.96%; E542K: 14.13%) and kinase (H1047R: 11.96%) hotspot mutations, and found that only the helical mutations had a high cumulative proportion for APOBEC signatures (SBS2* and SBS13*) (Figure <xref rid="cam44717-fig-0005" ref-type="fig">5C</xref>). Then, We related the <italic toggle="yes">PIK3CA</italic> helical mutations to each APOBEC signatures, and observed a significant increase for mutational exposure of APOBEC signatures in samples harboring helical domain mutations (Figure <xref rid="cam44717-fig-0005" ref-type="fig">5D‐E</xref>). Significantly, tumors carrying a hotspot mutation E545K significantly hold a high degree of contribution fraction of SBS2*, yet hotspot mutation E542K can not bring significant benefits to SBS2*, as well as the other mutations (Figure <xref rid="cam44717-fig-0005" ref-type="fig">5D</xref>), implying that only mutation E545K can affect the benefit of the overall mutation data of the sample on SBS2* compared with other mutations. Similarly, we found that although the E542K mutation significantly increased the benefits of SBS13*, the significant intensity of the increase was not as high as that of E545K (Median: 0.146 vs. 0.172) (Figure <xref rid="cam44717-fig-0005" ref-type="fig">5E</xref>), indicating that the E545K mutation in <italic toggle="yes">PIK3CA</italic> can accelerate the increase of SBS13* activity. Furthermore, from the perspective of gene itself, the CCA of <italic toggle="yes">PIK3CA</italic> genetic hotspot mutations for APOBEC signatures was significantly higher than that of other mutations (Figure <xref rid="cam44717-fig-0005" ref-type="fig">5F‐G</xref>). However, compared with E542K mutation, the effect of E545K mutation is more significant, indicating E545K among <italic toggle="yes">PIK3CA</italic> mutation is more closely associated with APOBEC signatures. In a word, <italic toggle="yes">PIK3CA</italic> helical mutation E545K contributes more significantly to APOBEC signatures, suggesting that they are strongly association with APOBEC.</p>
    </sec>
    <sec id="cam44717-sec-0021">
      <label>3.6</label>
      <title><styled-content style="fixed-case" toggle="no">Cumulative contribution abundance</styled-content> analysis displaying the relationship between age signature and <styled-content style="fixed-case" toggle="no">TP53</styled-content> typical hotspot mutations</title>
      <p>In previous study, the results of <italic toggle="yes">TP53</italic> mutations on mutational signatures indicates that driver mutations of <italic toggle="yes">TP53</italic> mutations are associated with specific mutation processes in human cancers, such as colon, skin, bladder, lung, and liver cancers.<xref rid="cam44717-bib-0051" ref-type="bibr"><sup>51</sup></xref>, <xref rid="cam44717-bib-0052" ref-type="bibr"><sup>52</sup></xref> They only mentioned that the most frequent <italic toggle="yes">TP53</italic> mutations were associated with the most commonly observed age signature which featured by C&gt;T transitions at CpG dinucleotides. It is worth considering that there is no detailed report on the association between <italic toggle="yes">TP53</italic> typical hotspot mutations and age signature in the related studies of ESCC, including the previous large cohort analysis of ESCC.<xref rid="cam44717-bib-0047" ref-type="bibr"><sup>47</sup></xref>, <xref rid="cam44717-bib-0053" ref-type="bibr"><sup>53</sup></xref> Here, we analyzed the association between <italic toggle="yes">TP53</italic> mutations and age signature confirming that age signature was associated with <italic toggle="yes">TP53</italic> mutations via CCA enrichment analysis (Regular tumors of ESCC1073‐EXON: 715 tumors with non‐silent <italic toggle="yes">TP53</italic> mutations and a median increase CCA of 0.0823 per sample; q &lt; 0.0001, <italic toggle="yes">p</italic> &lt; 0.0001; ESCC1073‐EXON: 728 tumors with non‐silent <italic toggle="yes">TP53</italic> mutations and a median increase CCA of 0.085 per sample; q &lt; 0.0001, <italic toggle="yes">p</italic> &lt; 0.0001; Figure <xref rid="cam44717-supitem-0008" ref-type="supplementary-material">S8</xref>D). Moreover, mutational signature enrichment analyses also revealed the strong relationship between <italic toggle="yes">TP53</italic> mutation and age signature activity (Figure <xref rid="cam44717-supitem-0008" ref-type="supplementary-material">S8</xref>D). It is worth noting that <italic toggle="yes">TP53</italic> was mainly enriched with C&gt;T substitutions (44.51%) with a large proportion of them were preferentially contributed to age signatures (SBS1*) (Figure <xref rid="cam44717-fig-0006" ref-type="fig">6A</xref>). We screened the six kinds of hotspot mutations with the highest risk rate (R342*: 4.07%; R213*: 3.37%; R282W: 2.95%; R175H: 2.81%; R273H: 2.53%; R248Q: 2.11%) and analyzed their association with mutational signatures. We found that except R175H, the other five hotspots preferred the age signatures (SBS1*) (Figure <xref rid="cam44717-fig-0006" ref-type="fig">6A</xref>), which indicated that there was a potential mechanism between these hotspots and age signatures (SBS1*). Compared with other mutations, tumors harboring at least one of these hotspots will significantly increase its contribution to age signature (SBS1*) (Figure <xref rid="cam44717-fig-0006" ref-type="fig">6B</xref>). Actually, although R282W can improve the contribution of the sample to age signature (SBS1*) (R282W vs. other mutation vs. wild‐type: median increase of 0.367 vs. 0.306 vs. 0.276), only hotspot mutation R342* can significantly affect the benefit of the whole mutation data of the sample to age signature (SBS1*) (R342* vs. other mutation vs. wild‐type: median increase of 0.388 vs. 0.305 vs. 0.276; Figure <xref rid="cam44717-fig-0006" ref-type="fig">6B</xref>), indicating that R342* mutation is the primary factor to increase the activity of age signature (SBS1*). However, from the perspective of gene mutation itself, the CCA of <italic toggle="yes">TP53</italic> typical hotspot mutations for age signatures was significantly higher than that of other mutations (Figure <xref rid="cam44717-fig-0006" ref-type="fig">6C</xref>), which indicated that except for R342* and R282W mutations, the other four hot spot mutations could not significantly improve the overall mutation contribution level of the sample, but they are still involved in the specific mutational process. In addition, under age signature (SBS1*), tumors with CCA of <italic toggle="yes">TP53</italic> no less than 0.06 were significantly associated with poor prognoses (<italic toggle="yes">p</italic> = 0.44, Figure <xref rid="cam44717-supitem-0007" ref-type="supplementary-material">S7</xref>A). Notably, CCA of <italic toggle="yes">TP53</italic> in tumors carrying <italic toggle="yes">TP53</italic> mutation R248Q were more than 0.06, and those cases were associated with deceased survival outcomes (Figure <xref rid="cam44717-supitem-0008" ref-type="supplementary-material">S8</xref>E). Multivariate cox model shows that <italic toggle="yes">TP53</italic> hotspot mutation R248Q are independent prognosticators for poor survival in ESCC (Figure <xref rid="cam44717-supitem-0008" ref-type="supplementary-material">S8</xref>F). Finally, we also found that <italic toggle="yes">TP53</italic> small INDEL mutations were related to New3 (ID signature; Figure <xref rid="cam44717-supitem-0008" ref-type="supplementary-material">S8</xref>G).</p>
      <fig position="float" fig-type="FIGURE" id="cam44717-fig-0006">
        <label>FIGURE 6</label>
        <caption>
          <p>Cumulative contribution abundance enrichment analysis identifies an association between somatic <italic toggle="yes">TP53</italic> mutations and activity of SBS1* in esophageal squamous cell carcinoma (ESCC). (A) Mutation trend and hotspot analysis of <italic toggle="yes">TP53</italic> non‐silent mutations: the pie chart on the top left shows the proportion of six mutation types, and the pie chart on the top right shows the proportion of coding protein, with the name of the protein that accounts for a large proportion. Each color in the figure below represents a mutation feature, and the statistical proportion of the contribution of six mutation types to each mutation signature is on the left, a column represents a mutation type; The figure on the right shows the contribution abundance of classical hotspot mutant protein to each signature, and a column represents a classical mutant protein. (B) The violin diagram shows the difference of contribution to SBS1* between the samples with <italic toggle="yes">TP53</italic> hotspot mutation and other types of samples, while (C) shows the difference of contribution abundance between samples with <italic toggle="yes">TP53</italic> hotspot mutations and other samples. The Wilcoxon rank sum test with two‐sided is used here, * represents (0.01 ≤ <italic toggle="yes">p</italic> &lt; 0.05), ** (0.001 ≤ <italic toggle="yes">p</italic> &lt; 0.01), *** represents (<italic toggle="yes">p</italic> &lt; 0.001), and ns represents (<italic toggle="yes">p</italic> ≥ 0.05)</p>
        </caption>
        <graphic xlink:href="CAM4-11-4053-g001" position="anchor" id="jats-graphic-13"/>
      </fig>
    </sec>
    <sec id="cam44717-sec-0022">
      <label>3.7</label>
      <title>Image analysis based on c<styled-content style="fixed-case" toggle="no">umulative contribution abundance</styled-content> matrix of genes</title>
      <p>Considering the limitation of relatively short follow‐up time, we set three‐year survival as a threshold and divided the sample into five groups (Table <xref rid="cam44717-supitem-0016" ref-type="supplementary-material">S7</xref>): G1) Survival status, follow‐up time is less than 3 years; G2) survival status, follow‐up time is not less than 3 years; G3) death status, follow‐up time is not less than 3 years; G4) death status, follow‐up time is less than 3 years; G5) others (rejection). Because G1 individuals are living and their follow‐up time is less than 3 years, we will use G2‐3‐4 groups for the next analysis and mining, as shown in Table <xref rid="cam44717-supitem-0016" ref-type="supplementary-material">S7</xref>A. Limited by clinical information, and to better evaluate the prognosis, we especially compared G2 and G4 groups. The above grouped samples were respectively converted into images by CCA matrix (Figure <xref rid="cam44717-supitem-0009" ref-type="supplementary-material">S9</xref>A) for deep learning model analysis. For choosing an ideal model, we randomly select a feature as a template for training, and take the high average accuracy as the judgment basis for model selection. Here we choose one SBS signature (New) as an example, as shown in Table <xref rid="cam44717-supitem-0016" ref-type="supplementary-material">S7</xref>B. Four of them have higher accuracy, and they are Resnet50 (68.571%), DenseNet121 (71.429%), MoblieNetV2 (68.571%), and InceptionV4 (68.571%). To test the stability of our model, the above four models were trained for 10 times. In the training process, the model parameter random seed was fixed, other parameters are the same. Finally, through the analysis, we found that DenseNet‐121 model has a higher average accuracy (Table <xref rid="cam44717-supitem-0016" ref-type="supplementary-material">S7</xref>B; Figure <xref rid="cam44717-supitem-0009" ref-type="supplementary-material">S9</xref>B). Consequently, we chose DenseNet‐121 as a model to analyze all signatures, the full schematic representation as shown in Figure <xref rid="cam44717-supitem-0009" ref-type="supplementary-material">S9</xref>C. In the process, a stochastic gradient descent method<xref rid="cam44717-bib-0054" ref-type="bibr"><sup>54</sup></xref> was used with an initial learning rate of 0.01, weight decay of 10<sup>–4</sup> and momentum of 0.7 in the process of training. Next, dropout, data augmentation and L2‐regularization were applied to prevent overfitting. The above parameter sets were properly tuned for DenseNet‐121 model. Then, for testing the stability of data and finding the global optimal solution, the model DenseNet‐121 was trained 10 times for each sub‐feature data of G2‐G4. Random seed was set free in the training process. That some less accuracy than others may be a local optimal solution because stochastic gradient descent method was used as the optimizer in the training process. We found that the accuracy was comparatively stable to each sub‐feature and relatively higher in mutational SBS3*, New and SBS17b* (Figure <xref rid="cam44717-supitem-0009" ref-type="supplementary-material">S9</xref>D), suggesting that the beneficial feasibility of this conversion method of the CCA matrix image data of gene. Simultaneously, the results are given the best accuracy of G2‐G4 is the sub‐feature SBS17b* (77.500%), followed by SBS3* (72.500%) and New (71.429%). Furthermore, the probability distribution over the above three subfeatures of G3 group in the G2‐G4 was tested. Interestingly, the distribution of G3 group is more likely to fall on G2 group (Figure <xref rid="cam44717-supitem-0009" ref-type="supplementary-material">S9</xref>E). So further the model DenseNet‐121 was also trained 10 times for each subfeature data of G2G3‐G4 (Figure <xref rid="cam44717-supitem-0009" ref-type="supplementary-material">S9</xref>D). The results show that the best accuracy of G2G3‐G4 is the sub‐feature SBS3* (76.190%), followed by New (72.973%), SBS16* (71.111%), and SBS17b* (70.732%), as shown in Table <xref rid="cam44717-supitem-0016" ref-type="supplementary-material">S7</xref>C. This illustrate that the G3 group addition has slight effect on the classification results. Additionally, the mutational signatures such as SBS3*, New and SBS17b* still have a high degree of explanation for G2‐G4 and G2G3‐G4 (Figure <xref rid="cam44717-fig-0007" ref-type="fig">7</xref>). Finally, we found that the survival group or the samples with a follow‐up time of no less than 3 years had a higher contribution to SBS3* and SBS17b*, respectively (Figure <xref rid="cam44717-supitem-0009" ref-type="supplementary-material">S9</xref>F).</p>
      <fig position="float" fig-type="FIGURE" id="cam44717-fig-0007">
        <label>FIGURE 7</label>
        <caption>
          <p>Application of cumulative contribution abundance matrix of genes in prognosis for esophageal squamous cell carcinoma. The sensitivity‐specificity curve of set classifier at the test sample sets for urgent versus non‐urgent binary classification</p>
        </caption>
        <graphic xlink:href="CAM4-11-4053-g004" position="anchor" id="jats-graphic-15"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="discussion" id="cam44717-sec-0023">
    <label>4</label>
    <title>DISCUSSION</title>
    <p>Here, we provide an integrated mutational signature analysis framework with a CCA model of genes, achieve a meta‐analysis of 1073 ESCC samples, and verify the practicability and application value of our framework. Via this framework, we obtained known and uncovered previously undescribed signatures (including 12 SBS signatures and 9 ID signatures) from 508 WGS tumors of 1073 ESCC cases. And further identified and highlighted an association between <italic toggle="yes">PIK3CA</italic> helical mutation E545K and activity of APOBEC signatures. Similarly, we also reported that age signature and the hotspot mutation R342* of <italic toggle="yes">TP53</italic>, and <italic toggle="yes">TP53</italic> (R248Q) is a poor predictor for ESCC. In addition, the CCA matrix image data of genes under mutational signatures New, SBS3*, and SBS17b* were calculated. This is helpful for the preliminary evaluation of short‐term prognosis.</p>
    <p>In addition to feature extraction and sample contribution analysis, we can also assign graph variation features to each sample by the designed framework, or even each gene, and then CCA of gene under a certain signature can be also obtained. Yet, compared with the previously published software,<xref rid="cam44717-bib-0023" ref-type="bibr"><sup>23</sup></xref> our framework spends more time on a de novo extraction of signature analysis. The reason is that we design a correction process “Re‐updated the initial value” and a solution space process “build a solution space.”. Hence, this is a weakness in the framework that need to be optimized in the future. However, our framework provides a new idea for understanding the panorama of tumor mutational processes, and help scientific researchers to study the mechanisms of tumor progression. It is of great application value to study the characteristics and statistical distribution of one gene under a certain signature by assigning the signature. In this study, based on previous reports<xref rid="cam44717-bib-0023" ref-type="bibr"><sup>23</sup></xref>, <xref rid="cam44717-bib-0024" ref-type="bibr"><sup>24</sup></xref>, <xref rid="cam44717-bib-0047" ref-type="bibr"><sup>47</sup></xref> and statistical evaluation (Figure <xref rid="cam44717-fig-0004" ref-type="fig">4b</xref>, Figure <xref rid="cam44717-supitem-0006" ref-type="supplementary-material">S6</xref>B), we confirmed the background of expected mutational signatures of ESCC. Concurrently, 717 cancer‐related genes from the COSMIC census (<ext-link xlink:href="https://cancer.sanger.ac.uk/census" ext-link-type="uri">https://cancer.sanger.ac.uk/census</ext-link>, Table <xref rid="cam44717-supitem-0014" ref-type="supplementary-material">S5</xref>) were selected as the base to calculate CCA. Due to the inconsistent sequencing background of the data, we uniformly analyzed the data of coding regions, and calculated the contribution of each sample to these signatures for subsequent analysis. However, this analysis will have some limitations. To avoid the impact of this limitation, we are committed to explore the ubiquitous signatures such as APOBEC signatures and age signatures, and discuss those frequently mutated genes that present in ESCC, such as <italic toggle="yes">TP53</italic> and <italic toggle="yes">PIK3CA</italic>.</p>
    <p>Previous reports have revealed that mutations in the helix domain and kinase domain of <italic toggle="yes">PIK3CA</italic> cause activation through different mechanisms, and the mutation process may be related to driving mutations in a variety of cancers.<xref rid="cam44717-bib-0055" ref-type="bibr"><sup>55</sup></xref> In ESCC studies, it was also mentioned that <italic toggle="yes">PIK3CA</italic> mutation was associated with the APOBEC signatures.<xref rid="cam44717-bib-0050" ref-type="bibr"><sup>50</sup></xref>, <xref rid="cam44717-bib-0051" ref-type="bibr"><sup>51</sup></xref> Furthermore, we found that there was a close relationship between APOBEC signatures and <italic toggle="yes">PIK3CA</italic> mutations in the meta‐analysis of 1073 ESCC tumors, especially <italic toggle="yes">PIK3CA</italic> mutation E545K. In conclusion, APOBEC are strongly linked to driver mutations, especially the known hotspot mutation E545K of <italic toggle="yes">PIK3CA</italic>, suggests that there is a mechanism between APOBEC and <italic toggle="yes">PIK3CA</italic>, which needs to be deeply verified by a large number of subsequent experiments.</p>
    <p>Next, we analyzed the association of <italic toggle="yes">TP53</italic> hotspot mutations and mutational signature. Notably, the most frequent <italic toggle="yes">TP53</italic> mutations found in ESCC were associated with the most commonly observed mutational signature, age signature, which reflects the natural degradation of 5‐methylcyto sine to thymine.<xref rid="cam44717-bib-0056" ref-type="bibr"><sup>56</sup></xref> In particular, the mutation R342* of <italic toggle="yes">TP53</italic> can affect the mutation process of tumor occurrence and development, resulting in a significant increase contribution of the sample to age signature (Figure <xref rid="cam44717-fig-0006" ref-type="fig">6B</xref>). This led us to put forward the hypothesis that the mutation R342* of <italic toggle="yes">TP53</italic> in ESCC, which is the primary factor to increase the activity of age signature. In many tumor types, driver mutations of <italic toggle="yes">TP53</italic> appear to be strongly associated with multiple signatures, and their probably arises due to the selection of loss‐of‐function and dominant‐negative alleles, which are generated by specific mutational processes.<xref rid="cam44717-bib-0051" ref-type="bibr"><sup>51</sup></xref>, <xref rid="cam44717-bib-0052" ref-type="bibr"><sup>52</sup></xref> In our analysis, <italic toggle="yes">TP53</italic> mutations R213* was also shown to be an independent prognostic factor.</p>
    <p>In addition to the CCA matrix image, deep convolutional neural network denseNet‐121 was used to analyze and the CCA matrix image data of gene in SBS3* and SBS17b*, which can be preliminarily distinguished the shortened survival outcome (follow‐up time no less than 3 years). This finding indicates that the results of this method serves as one of the criteria to evaluate the prognosis of 3‐year survival. Combined with AI technology, our designed scheme directly provides a new way to explore from the single gene relationship research to the multi gene association analysis. In general, the number of individuals studied in this paper is relatively small, which is one of the shortcomings of model learning. We hope to further achieve the useful information in the era of big data. More excellent learning model is also one of the improvement ideas to obtain accurate results, which needs further research in the future. At the same time, complete clinical information, including treatment methods, medication information, extended follow‐up time and so on, is of great clinical significance for the further exploration of this idea. We are reasonably optimistic that in the future, CCA matrix of genes can be used to evaluate the prognosis, metastasis risk, recurrence risk, and even provide medication guidance and suggestions for individuals.</p>
    <p>Overall, it is indispensable to understand and explore the mechanism of tumorigenesis and development by studying the relationship between genes and mutational signatures. The potential application of CCA of genes needs to be further studied and explored, such as giving some specific gene lists, forming image pictures, and perhaps evaluating prognosis and guiding medication through deep learning.</p>
  </sec>
  <sec sec-type="COI-statement" id="cam44717-sec-0025">
    <title>CONFLICT OF INTEREST</title>
    <p>The authors declare have no conflict of interest.</p>
  </sec>
  <sec id="cam44717-sec-0026">
    <title>AUTHOR CONTRIBUTIONS</title>
    <p>Zhenzhang Li and Wen Luo developed the computational method, drafted the manuscript, implemented the software tool and evaluated performance of the software tool. Haihua Liang and Shaoan Zhang advised on model design and guided implementation/evaluation. All authors have read and agreed to the published version of the manuscript.</p>
  </sec>
  <sec id="cam44717-sec-0027">
    <title>ETHICS STATEMENT</title>
    <p>No ethics approval was required for this review that did not involve patients or patient data.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supporting information</title>
    <supplementary-material id="cam44717-supitem-0001" position="float" content-type="local-data">
      <caption>
        <p>
Figure S1
</p>
      </caption>
      <media xlink:href="CAM4-11-4053-s001.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="cam44717-supitem-0002" position="float" content-type="local-data">
      <caption>
        <p>
Figure S2
</p>
      </caption>
      <media xlink:href="CAM4-11-4053-s007.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="cam44717-supitem-0003" position="float" content-type="local-data">
      <caption>
        <p>
Figure S3
</p>
      </caption>
      <media xlink:href="CAM4-11-4053-s013.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="cam44717-supitem-0004" position="float" content-type="local-data">
      <caption>
        <p>
Figure S4
</p>
      </caption>
      <media xlink:href="CAM4-11-4053-s010.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="cam44717-supitem-0005" position="float" content-type="local-data">
      <caption>
        <p>
Figure S5
</p>
      </caption>
      <media xlink:href="CAM4-11-4053-s015.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="cam44717-supitem-0006" position="float" content-type="local-data">
      <caption>
        <p>
Figure S6
</p>
      </caption>
      <media xlink:href="CAM4-11-4053-s016.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="cam44717-supitem-0007" position="float" content-type="local-data">
      <caption>
        <p>
Figure S7
</p>
      </caption>
      <media xlink:href="CAM4-11-4053-s008.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="cam44717-supitem-0008" position="float" content-type="local-data">
      <caption>
        <p>
Figure S8
</p>
      </caption>
      <media xlink:href="CAM4-11-4053-s012.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="cam44717-supitem-0009" position="float" content-type="local-data">
      <caption>
        <p>
Figure S9
</p>
      </caption>
      <media xlink:href="CAM4-11-4053-s003.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="cam44717-supitem-0010" position="float" content-type="local-data">
      <caption>
        <p>
Table S1
</p>
      </caption>
      <media xlink:href="CAM4-11-4053-s005.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="cam44717-supitem-0011" position="float" content-type="local-data">
      <caption>
        <p>
Table S2
</p>
      </caption>
      <media xlink:href="CAM4-11-4053-s011.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="cam44717-supitem-0012" position="float" content-type="local-data">
      <caption>
        <p>
Table S3
</p>
      </caption>
      <media xlink:href="CAM4-11-4053-s006.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="cam44717-supitem-0013" position="float" content-type="local-data">
      <caption>
        <p>
Table S4
</p>
      </caption>
      <media xlink:href="CAM4-11-4053-s009.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="cam44717-supitem-0014" position="float" content-type="local-data">
      <caption>
        <p>
Table S5
</p>
      </caption>
      <media xlink:href="CAM4-11-4053-s004.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="cam44717-supitem-0015" position="float" content-type="local-data">
      <caption>
        <p>
Table S6
</p>
      </caption>
      <media xlink:href="CAM4-11-4053-s014.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="cam44717-supitem-0016" position="float" content-type="local-data">
      <caption>
        <p>
Table S7
</p>
      </caption>
      <media xlink:href="CAM4-11-4053-s002.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="cam44717-sec-0024">
    <title>ACKNOWLEDGMENTS</title>
    <p>This work is supported by the project of the young creative talents of department education of Guangdong (Natural Science), Grant No. 2019KQNCX067; Science and technology planning project of Guangzhou, Grant No. 006259497026; The NNSF of China (No.11771101), NNSF of Guangdong Province (2021); And the project of promoting research capabilities for key constructed disciplines in Guangdong Province (No.2021ZDJS028).</p>
  </ack>
  <sec sec-type="data-availability" id="cam44717-sec-0029">
    <title>DATA AVAILABILITY STATEMENT</title>
    <p><italic toggle="yes">RNMF</italic> is publicly available at <ext-link xlink:href="https://github.com/zhenzhang-li/RNMF" ext-link-type="uri" specific-use="software is-supplemented-by">https://github.com/zhenzhang‐li/RNMF</ext-link> and will be regularly maintained and updated. A detailed description of installing/running RNMF in the GitHub repository. The data sets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.</p>
  </sec>
  <ref-list content-type="cited-references" id="cam44717-bibl-0001">
    <title>REFERENCES</title>
    <ref id="cam44717-bib-0001">
      <label>1</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0001"><string-name><surname>Stratton</surname><given-names>MR</given-names></string-name>, <string-name><surname>Campbell</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Futreal</surname><given-names>PA</given-names></string-name>. <article-title>The cancer genome</article-title>. <source>Nature</source>. <year>2009</year>;<volume>458</volume>:<fpage>719</fpage>‐<lpage>724</lpage>.<pub-id pub-id-type="pmid">19360079</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0002">
      <label>2</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0002"><string-name><surname>Pfeifer</surname><given-names>GP</given-names></string-name>. <article-title>Environmental exposures and mutational patterns of cancer genomes</article-title>. <source>Genome Med</source>. <year>2010</year>;<volume>2</volume>:<fpage>54</fpage>‐<lpage>57</lpage>.<pub-id pub-id-type="pmid">20707934</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0003">
      <label>3</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0003"><string-name><surname>Boland</surname><given-names>CR</given-names></string-name>, <string-name><surname>Goel</surname><given-names>A</given-names></string-name>. <article-title>Microsatellite instability in colorectal cancer</article-title>. <source>Gastroenterology</source>. <year>2020</year>;<volume>138</volume>:<fpage>2073</fpage>‐<lpage>2087</lpage>.</mixed-citation>
    </ref>
    <ref id="cam44717-bib-0004">
      <label>4</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0004"><string-name><surname>Nik‐Zainal</surname><given-names>S</given-names></string-name>, <string-name><surname>Alexandrov</surname><given-names>LB</given-names></string-name>, <string-name><surname>Wedge</surname><given-names>DC</given-names></string-name>, et al. <article-title>Mutational processes molding the genomes of 21 breast cancers</article-title>. <source>Cell</source>. <year>2012</year>;<volume>149</volume>:<fpage>979</fpage>‐<lpage>993</lpage>.<pub-id pub-id-type="pmid">22608084</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0005">
      <label>5</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0005"><string-name><surname>Alexandrov</surname><given-names>LB</given-names></string-name>, <string-name><surname>Stratton</surname><given-names>MR</given-names></string-name>. <article-title>Mutational signatures: the patterns of somatic mutations hidden in cancer genomes</article-title>. <source>Curr Opin Genet Dev</source>. <year>2014</year>;<volume>24</volume>:<fpage>52</fpage>‐<lpage>60</lpage>.<pub-id pub-id-type="pmid">24657537</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0006">
      <label>6</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0006"><string-name><surname>Stratton</surname><given-names>MR</given-names></string-name>. <article-title>Exploring the genomes of cancer cells: progress and promise</article-title>. <source>Science</source>. <year>2011</year>;<volume>331</volume>:<fpage>1553</fpage>‐<lpage>1558</lpage>.<pub-id pub-id-type="pmid">21436442</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0007">
      <label>7</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0007"><string-name><surname>Letouzé</surname><given-names>E</given-names></string-name>, <string-name><surname>Shinde</surname><given-names>J</given-names></string-name>, <string-name><surname>Renault</surname><given-names>V</given-names></string-name>, et al. <article-title>Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis</article-title>. <source>Nat Commun</source>. <year>2017</year>;<volume>8</volume>:<fpage>1</fpage>‐<lpage>13</lpage>.<pub-id pub-id-type="pmid">28232747</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0008">
      <label>8</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0008"><string-name><surname>Davies</surname><given-names>H</given-names></string-name>, <string-name><surname>Glodzik</surname><given-names>D</given-names></string-name>, <string-name><surname>Morganella</surname><given-names>S</given-names></string-name>, et al. <article-title>HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures</article-title>. <source>Nat Med</source>. <year>2017</year>;<volume>23</volume>:<fpage>517</fpage>‐<lpage>525</lpage>.<pub-id pub-id-type="pmid">28288110</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0009">
      <label>9</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0009"><string-name><surname>Ma</surname><given-names>J</given-names></string-name>, <string-name><surname>Setton</surname><given-names>J</given-names></string-name>, <string-name><surname>Lee</surname><given-names>NY</given-names></string-name>, <string-name><surname>Riaz</surname><given-names>N</given-names></string-name>, <string-name><surname>Powell</surname><given-names>SN</given-names></string-name>. <article-title>The therapeutic significance of mutational signatures from DNA repair deficiency in cancer</article-title>. <source>Nat Commun</source>. <year>2018</year>;<volume>9</volume>:<fpage>1</fpage>‐<lpage>12</lpage>.<pub-id pub-id-type="pmid">29317637</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0010">
      <label>10</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0010"><string-name><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name><surname>Jia</surname><given-names>M</given-names></string-name>, <string-name><surname>He</surname><given-names>Z</given-names></string-name>, <string-name><surname>Liu</surname><given-names>XS</given-names></string-name>. <article-title>APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non‐small cell lung cancer</article-title>. <source>Oncogene</source>. <year>2018</year>;<volume>37</volume>:<fpage>3924</fpage>‐<lpage>3936</lpage>.<pub-id pub-id-type="pmid">29695832</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0011">
      <label>11</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0011"><string-name><surname>Harris</surname><given-names>RS</given-names></string-name>. <article-title>Cancer mutation signatures, DNA damage mechanisms, and potential clinical implications</article-title>. <source>Genome Med</source>. <year>2013</year>;<volume>5</volume>(<issue>9</issue>):<fpage>87</fpage>.<pub-id pub-id-type="pmid">24073723</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0012">
      <label>12</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0012"><string-name><surname>Wagener</surname><given-names>R</given-names></string-name>, <string-name><surname>Alexandrov</surname><given-names>LB</given-names></string-name>, <string-name><surname>Montesinos‐Rongen</surname><given-names>M</given-names></string-name>, et al. <article-title>Analysis of mutational signatures in exomes from B‐cell lymphoma cell lines suggest APOBEC3 family members to be involved in the pathogenesis of primary effusion lymphoma</article-title>. <source>Leukemia</source>. <year>2015</year>;<volume>29</volume>:<fpage>1612</fpage>‐<lpage>1615</lpage>.<pub-id pub-id-type="pmid">25650088</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0013">
      <label>13</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0013"><string-name><surname>Helleday</surname><given-names>T</given-names></string-name>, <string-name><surname>Eshtad</surname><given-names>S</given-names></string-name>, <string-name><surname>Nik‐Zainal</surname><given-names>S</given-names></string-name>. <article-title>Mechanisms underlying mutational signatures in human cancers</article-title>. <source>Nat Rev Genet</source>. <year>2014</year>;<volume>15</volume>:<fpage>585</fpage>‐<lpage>598</lpage>.<pub-id pub-id-type="pmid">24981601</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0014">
      <label>14</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0014"><string-name><surname>Kim</surname><given-names>J</given-names></string-name>, <string-name><surname>Mouw</surname><given-names>KW</given-names></string-name>, <string-name><surname>Polak</surname><given-names>P</given-names></string-name>, et al. <article-title>Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors</article-title>. <source>Nat Genet</source>. <year>2016</year>;<volume>48</volume>:<fpage>600</fpage>‐<lpage>606</lpage>.<pub-id pub-id-type="pmid">27111033</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0015">
      <label>15</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0015"><string-name><surname>Alexandrov</surname><given-names>LB</given-names></string-name>, <string-name><surname>Nik‐Zainal</surname><given-names>S</given-names></string-name>, <string-name><surname>Wedge</surname><given-names>DC</given-names></string-name>, <string-name><surname>Campbell</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Stratton</surname><given-names>MR</given-names></string-name>. <article-title>Deciphering signatures of mutational processes operative in human cancer</article-title>. <source>Cell Rep</source>. <year>2013</year>;<volume>2013</volume>(<issue>3</issue>):<fpage>246</fpage>‐<lpage>259</lpage>.</mixed-citation>
    </ref>
    <ref id="cam44717-bib-0016">
      <label>16</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0016"><string-name><surname>Gehring</surname><given-names>JS</given-names></string-name>, <string-name><surname>Fischer</surname><given-names>B</given-names></string-name>, <string-name><surname>Lawrence</surname><given-names>M</given-names></string-name>, <string-name><surname>Huber</surname><given-names>W</given-names></string-name>. <article-title>SomaticSignatures: inferring mutational signatures from single‐nucleotide variants</article-title>. <source>Bioinformatics</source>. <year>2015</year>;<volume>31</volume>:<fpage>3673</fpage>‐<lpage>3675</lpage>.<pub-id pub-id-type="pmid">26163694</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0017">
      <label>17</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0017"><string-name><surname>Shiraishi</surname><given-names>Y</given-names></string-name>, <string-name><surname>Tremmel</surname><given-names>G</given-names></string-name>, <string-name><surname>Miyano</surname><given-names>S</given-names></string-name>, <string-name><surname>Stephens</surname><given-names>M</given-names></string-name>. <article-title>A simple model‐based approach to inferring and visualizing cancer mutation signatures</article-title>. <source>PLoS Genet</source>. <year>2015</year>;<volume>11</volume>:<elocation-id>e1005657</elocation-id>.<pub-id pub-id-type="pmid">26630308</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0018">
      <label>18</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0018"><string-name><surname>Rosales</surname><given-names>RA</given-names></string-name>, <string-name><surname>Drummond</surname><given-names>RD</given-names></string-name>, <string-name><surname>Valieris</surname><given-names>R</given-names></string-name>, <string-name><surname>Dias‐Neto</surname><given-names>E</given-names></string-name>, <string-name><surname>da Silva</surname><given-names>IT</given-names></string-name>. <article-title>signeR: an empirical Bayesian approach to mutational signature discovery</article-title>. <source>Bioinformatics</source>. <year>2017</year>;<volume>33</volume>:<fpage>8</fpage>‐<lpage>16</lpage>.<pub-id pub-id-type="pmid">27591080</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0019">
      <label>19</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0019"><string-name><surname>Ardin</surname><given-names>M</given-names></string-name>, <string-name><surname>Cahais</surname><given-names>V</given-names></string-name>, <string-name><surname>Castells</surname><given-names>X</given-names></string-name>, et al. <article-title>MutSpec: a galaxy toolbox for streamlined analyses of somatic mutation spectra in human and mouse cancer genomes</article-title>. <source>BMC Bioinformatics</source>. <year>2016</year>;<volume>17</volume>:<fpage>170_1‐10</fpage>.<pub-id pub-id-type="pmid">27091472</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0020">
      <label>20</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0020"><string-name><surname>Blokzijl</surname><given-names>F</given-names></string-name>, <string-name><surname>Janssen</surname><given-names>R</given-names></string-name>, <string-name><surname>van Boxtel</surname><given-names>R</given-names></string-name>, <string-name><surname>Cuppen</surname><given-names>E</given-names></string-name>. <article-title>MutationalPatterns: comprehensive genome‐wide analysis of mutational processes</article-title>. <source>Genome Med</source>. <year>2018</year>;<volume>10</volume>:<fpage>33_1‐11</fpage>.<pub-id pub-id-type="pmid">29695279</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0021">
      <label>21</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0021"><string-name><surname>Xing</surname><given-names>R</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yu</surname><given-names>J</given-names></string-name>, et al. <article-title>Whole‐genome sequencing reveals novel tandem‐duplication hotspots and a prognostic mutational signature in gastric cancer</article-title>. <source>Nat Commun</source>. <year>2019</year>;<volume>10</volume>:<fpage>1</fpage>‐<lpage>13</lpage>.<pub-id pub-id-type="pmid">30602773</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0022">
      <label>22</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0022"><string-name><surname>Baez‐Ortega</surname><given-names>A</given-names></string-name>, <string-name><surname>Gori</surname><given-names>K</given-names></string-name>. <article-title>Computational approaches for discovery of mutational signatures in cancer</article-title>. <source>Brief Bioinform</source>. <year>2019</year>;<volume>20</volume>:<fpage>77</fpage>‐<lpage>88</lpage>.<pub-id pub-id-type="pmid">28968631</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0023">
      <label>23</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0023"><string-name><surname>Alexandrov</surname><given-names>LB</given-names></string-name>, <string-name><surname>Kim</surname><given-names>J</given-names></string-name>, <string-name><surname>Haradhvala</surname><given-names>NJ</given-names></string-name>, et al. <article-title>The repertoire of mutational signatures in human cancer</article-title>. <source>Nature</source>. <year>2020</year>;<volume>578</volume>:<fpage>94</fpage>‐<lpage>101</lpage>.<pub-id pub-id-type="pmid">32025018</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0024">
      <label>24</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0024"><string-name><surname>Alexandrov</surname><given-names>LB</given-names></string-name>, <string-name><surname>Nik‐Zainal</surname><given-names>S</given-names></string-name>, <string-name><surname>Wedge</surname><given-names>DC</given-names></string-name>, et al. <article-title>Signatures of mutational processes in human cancer</article-title>. <source>Nature</source>. <year>2013</year>;<volume>500</volume>:<fpage>415</fpage>‐<lpage>421</lpage>.<pub-id pub-id-type="pmid">23945592</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0025">
      <label>25</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0025"><string-name><surname>Poon</surname><given-names>SL</given-names></string-name>, <string-name><surname>Pang</surname><given-names>ST</given-names></string-name>, <string-name><surname>McPherson</surname><given-names>JR</given-names></string-name>, et al. <article-title>Genome‐wide mutational signatures of aristolochic acid and its application as a screening tool</article-title>. <source>Sci Transl Med</source>. <year>2013</year>;<volume>5</volume>:<fpage>197ra101</fpage>.</mixed-citation>
    </ref>
    <ref id="cam44717-bib-0026">
      <label>26</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0026"><string-name><surname>Poon</surname><given-names>SL</given-names></string-name>, <string-name><surname>Huang</surname><given-names>MN</given-names></string-name>, <string-name><surname>Choo</surname><given-names>Y</given-names></string-name>, et al. <article-title>Mutation signatures implicate aristolochic acid in bladder cancer development</article-title>. <source>Genome Med</source>. <year>2015</year>;<volume>7</volume>:<fpage>1</fpage>‐<lpage>10</lpage>.<pub-id pub-id-type="pmid">25606059</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0027">
      <label>27</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0027"><string-name><surname>Schulze</surname><given-names>K</given-names></string-name>, <string-name><surname>Imbeaud</surname><given-names>S</given-names></string-name>, <string-name><surname>Letouzé</surname><given-names>E</given-names></string-name>, et al. <article-title>Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets</article-title>. <source>Nat Genet</source>. <year>2015</year>;<volume>47</volume>:<fpage>505</fpage>‐<lpage>511</lpage>.<pub-id pub-id-type="pmid">25822088</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0028">
      <label>28</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0028"><string-name><surname>Merlevede</surname><given-names>J</given-names></string-name>, <string-name><surname>Droin</surname><given-names>N</given-names></string-name>, <string-name><surname>Qin</surname><given-names>T</given-names></string-name>, et al. <article-title>Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents</article-title>. <source>Nat Commun</source>. <year>2016</year>;<volume>7</volume>:<fpage>1</fpage>‐<lpage>13</lpage>.</mixed-citation>
    </ref>
    <ref id="cam44717-bib-0029">
      <label>29</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0029"><string-name><surname>Nik‐Zainal</surname><given-names>S</given-names></string-name>, <string-name><surname>Davies</surname><given-names>H</given-names></string-name>, <string-name><surname>Staaf</surname><given-names>J</given-names></string-name>, et al. <article-title>Landscape of somatic mutations in 560 breast cancer whole‐genome sequences</article-title>. <source>Nature</source>. <year>2016</year>;<volume>534</volume>:<fpage>47</fpage>‐<lpage>54</lpage>.<pub-id pub-id-type="pmid">27135926</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0030">
      <label>30</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0030"><string-name><surname>Petljak</surname><given-names>M</given-names></string-name>, <string-name><surname>Alexandrov</surname><given-names>LB</given-names></string-name>. <article-title>Understanding mutagenesis through delineation of mutational signatures in human cancer</article-title>. <source>Carcinogenesis</source>. <year>2016</year>;<volume>37</volume>:<fpage>531</fpage>‐<lpage>540</lpage>.<pub-id pub-id-type="pmid">27207657</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0031">
      <label>31</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0031"><string-name><surname>Polak</surname><given-names>P</given-names></string-name>, <string-name><surname>Kim</surname><given-names>J</given-names></string-name>, <string-name><surname>Braunstein</surname><given-names>LZ</given-names></string-name>, et al. <article-title>A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer</article-title>. <source>Nat Genet</source>. <year>2017</year>;<volume>9</volume>:<fpage>1476</fpage>‐<lpage>1486</lpage>.</mixed-citation>
    </ref>
    <ref id="cam44717-bib-0032">
      <label>32</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0032"><string-name><surname>Fischer</surname><given-names>A</given-names></string-name>, <string-name><surname>Illingworth</surname><given-names>CJR</given-names></string-name>, <string-name><surname>Campbell</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Mustonen</surname><given-names>V</given-names></string-name>. <article-title>EMu: probabilistic inference of mutational processes and their localization in the cancer genome</article-title>. <source>Genome Biol</source>. <year>2013</year>;<volume>14</volume>:<fpage>1</fpage>‐<lpage>10</lpage>.</mixed-citation>
    </ref>
    <ref id="cam44717-bib-0033">
      <label>33</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0033"><string-name><surname>Rosenthal</surname><given-names>R</given-names></string-name>, <string-name><surname>McGranahan</surname><given-names>N</given-names></string-name>, <string-name><surname>Herrero</surname><given-names>J</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>BS</given-names></string-name>, <string-name><surname>Swanton</surname><given-names>C</given-names></string-name>. <article-title>DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution</article-title>. <source>Genome Biol</source>. <year>2016</year>;<volume>17</volume>:<fpage>1</fpage>‐<lpage>11</lpage>.<pub-id pub-id-type="pmid">26753840</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0034">
      <label>34</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0034"><string-name><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name><surname>Wei</surname><given-names>L</given-names></string-name>, <string-name><surname>Feng</surname><given-names>X</given-names></string-name>, <string-name><surname>Ma</surname><given-names>Z</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>. <article-title>Pattern expression nonnegative matrix factorization: algorithm and applications to blind source separation</article-title>. <source>Comput Intell Neurosci</source>. <year>2008</year>;<volume>2008</volume>:<fpage>1</fpage>‐<lpage>10</lpage>.</mixed-citation>
    </ref>
    <ref id="cam44717-bib-0035">
      <label>35</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0035"><string-name><surname>Rajabi</surname><given-names>R</given-names></string-name>, <string-name><surname>Ghassemian</surname><given-names>H</given-names></string-name>. <article-title>Spectral unmixing of hyperspectral imagery using multilayer NMF</article-title>. <source>IEEE Geosci Remote Sens Lett</source>. <year>2014</year>;<volume>12</volume>:<fpage>38</fpage>‐<lpage>42</lpage>.</mixed-citation>
    </ref>
    <ref id="cam44717-bib-0036">
      <label>36</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0036"><string-name><surname>Alsabti</surname><given-names>K</given-names></string-name>, <string-name><surname>Ranka</surname><given-names>S</given-names></string-name>, <string-name><surname>Singh</surname><given-names>V</given-names></string-name>. <article-title>An efficient k‐means clustering algorithm</article-title>. <source>EECS</source>. <year>1997</year>;<volume>43</volume>.</mixed-citation>
    </ref>
    <ref id="cam44717-bib-0037">
      <label>37</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0037"><string-name><surname>Lin</surname><given-names>DC</given-names></string-name>, <string-name><surname>Dinh</surname><given-names>HQ</given-names></string-name>, <string-name><surname>Xie</surname><given-names>JJ</given-names></string-name>, et al. <article-title>Identification of distinct mutational patterns and new driver genes in oesophageal squamous cell carcinomas and adenocarcinomas</article-title>. <source>Gut</source>. <year>2018</year>;<volume>67</volume>:<fpage>1769</fpage>‐<lpage>1779</lpage>.<pub-id pub-id-type="pmid">28860350</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0038">
      <label>38</label>
      <mixed-citation publication-type="book" id="cam44717-cit-0038"><string-name><surname>Ketkar</surname><given-names>N</given-names></string-name>. <source>Introduction to Pytorch. Deep Learning with Python</source>. <publisher-name>Apress</publisher-name>; <year>2017</year>:<fpage>195</fpage>‐<lpage>208</lpage>.</mixed-citation>
    </ref>
    <ref id="cam44717-bib-0039">
      <label>39</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0039"><string-name><surname>He</surname><given-names>K</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name><surname>Ren</surname><given-names>S</given-names></string-name>, et al. <article-title>Deep residual learning for image recognition</article-title>. <source>CVPR</source>. <year>2016</year>:<fpage>770</fpage>‐<lpage>778</lpage>.</mixed-citation>
    </ref>
    <ref id="cam44717-bib-0040">
      <label>40</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0040"><string-name><surname>Huang</surname><given-names>G</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Z</given-names></string-name>, <string-name><surname>Van Der Maaten</surname><given-names>L</given-names></string-name>, et al. <article-title>Densely connected convolutional networks</article-title>. <source>CVPR</source>. <year>2017</year>:<fpage>4700</fpage>‐<lpage>4708</lpage>.</mixed-citation>
    </ref>
    <ref id="cam44717-bib-0041">
      <label>41</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0041"><string-name><surname>Pleiss</surname><given-names>G</given-names></string-name>, <string-name><surname>Chen</surname><given-names>D</given-names></string-name>, <string-name><surname>Huang</surname><given-names>G</given-names></string-name>, et al. <article-title>Memory‐efficient implementation of densenets</article-title>. <source>CoRR, abs/1707.06990</source>. <year>2017</year>:<volume>4</volume>.</mixed-citation>
    </ref>
    <ref id="cam44717-bib-0042">
      <label>42</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0042"><string-name><surname>Szegedy</surname><given-names>C</given-names></string-name>, <string-name><surname>Ioffe</surname><given-names>S</given-names></string-name>, <string-name><surname>Vanhoucke</surname><given-names>V</given-names></string-name>, et al. <article-title>Inception‐v4, inception‐resnet and the impact of residual connections on learning</article-title>. <source>AAAI Conference on Artificial Intelligence</source>. <year>2017</year>:<volume>31</volume>.</mixed-citation>
    </ref>
    <ref id="cam44717-bib-0043">
      <label>43</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0043"><string-name><surname>Sandler</surname><given-names>M</given-names></string-name>, <string-name><surname>Howard</surname><given-names>A</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>M</given-names></string-name>, et al. <article-title>Mobilenetv2: inverted residuals and linear bottlenecks</article-title>. <source>CVPR</source>. <year>2018</year>:<fpage>4510</fpage>‐<lpage>4520</lpage>.</mixed-citation>
    </ref>
    <ref id="cam44717-bib-0044">
      <label>44</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0044"><string-name><surname>Howard</surname><given-names>A</given-names></string-name>, <string-name><surname>Sandler</surname><given-names>M</given-names></string-name>, <string-name><surname>Chu</surname><given-names>G</given-names></string-name>, et al. <article-title>Searching for mobilenetv3</article-title>. <source>ICCV</source>. <year>2019</year>:<fpage>1314</fpage>‐<lpage>1324</lpage>.</mixed-citation>
    </ref>
    <ref id="cam44717-bib-0045">
      <label>45</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0045"><string-name><surname>Ramos</surname><given-names>AH</given-names></string-name>, <string-name><surname>Lichtenstein</surname><given-names>L</given-names></string-name>, <string-name><surname>Gupta</surname><given-names>M</given-names></string-name>, et al. <article-title>Oncotator: cancer variant annotation tool</article-title>. <source>Hum Mutat</source>. <year>2015</year>;<volume>36</volume>:<fpage>2423</fpage>‐<lpage>2429</lpage>.</mixed-citation>
    </ref>
    <ref id="cam44717-bib-0046">
      <label>46</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0046"><string-name><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>R</given-names></string-name>, <string-name><surname>Baade</surname><given-names>PD</given-names></string-name>, et al. <article-title>Cancer statistics in China, 2015</article-title>. <source>CA Cancer J Clin</source>. <year>2016</year>;<volume>66</volume>:<fpage>115</fpage>‐<lpage>132</lpage>.<pub-id pub-id-type="pmid">26808342</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0047">
      <label>47</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0047"><string-name><surname>Cui</surname><given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname><given-names>H</given-names></string-name>, <string-name><surname>Xi</surname><given-names>R</given-names></string-name>, et al. <article-title>Whole‐genome sequencing of 508 patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma</article-title>. <source>Cell Res</source>. <year>2020</year>;<volume>30</volume>:<fpage>902</fpage>‐<lpage>913</lpage>.<pub-id pub-id-type="pmid">32398863</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0048">
      <label>48</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0048"><string-name><surname>Burns</surname><given-names>MB</given-names></string-name>, <string-name><surname>Temiz</surname><given-names>NA</given-names></string-name>, <string-name><surname>Harris</surname><given-names>RS</given-names></string-name>. <article-title>Evidence for APOBEC3B mutagenesis in multiple human cancers</article-title>. <source>Nat Genet</source>. <year>2013</year>;<volume>45</volume>:<fpage>977</fpage>‐<lpage>983</lpage>.<pub-id pub-id-type="pmid">23852168</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0049">
      <label>49</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0049"><string-name><surname>Roberts</surname><given-names>SA</given-names></string-name>, <string-name><surname>Lawrence</surname><given-names>MS</given-names></string-name>, <string-name><surname>Klimczak</surname><given-names>LJ</given-names></string-name>, et al. <article-title>An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers</article-title>. <source>Nat Genet</source>. <year>2013</year>;<volume>45</volume>:<fpage>970</fpage>‐<lpage>976</lpage>.<pub-id pub-id-type="pmid">23852170</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0050">
      <label>50</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0050"><string-name><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>C</given-names></string-name>, et al. <article-title>Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma</article-title>. <source>Am J Hum Genet</source>. <year>2015</year>;<volume>96</volume>:<fpage>597</fpage>‐<lpage>611</lpage>.<pub-id pub-id-type="pmid">25839328</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0051">
      <label>51</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0051"><string-name><surname>Degasperi</surname><given-names>A</given-names></string-name>, <string-name><surname>Amarante</surname><given-names>TD</given-names></string-name>, <string-name><surname>Czarnecki</surname><given-names>J</given-names></string-name>, et al. <article-title>A practical framework and online tool for mutational signature analyses show intertissue variation and driver dependencies</article-title>. <source>Nat Cancer</source>. <year>2020</year>;<volume>1</volume>:<fpage>249</fpage>‐<lpage>263</lpage>.<pub-id pub-id-type="pmid">32118208</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0052">
      <label>52</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0052"><string-name><surname>Giacomelli</surname><given-names>AO</given-names></string-name>, <string-name><surname>Yang</surname><given-names>X</given-names></string-name>, <string-name><surname>Lintner</surname><given-names>RE</given-names></string-name>, et al. <article-title>Mutational processes shape the landscape of TP53 mutations in human cancer</article-title>. <source>Nat Genet</source>. <year>2018</year>;<volume>50</volume>:<fpage>1381</fpage>‐<lpage>1387</lpage>.<pub-id pub-id-type="pmid">30224644</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0053">
      <label>53</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0053"><string-name><surname>Li</surname><given-names>XC</given-names></string-name>, <string-name><surname>Wang</surname><given-names>MY</given-names></string-name>, <string-name><surname>Yang</surname><given-names>M</given-names></string-name>, et al. <article-title>A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma</article-title>. <source>Ann Oncol</source>. <year>2018</year>;<volume>29</volume>:<fpage>938</fpage>‐<lpage>944</lpage>.<pub-id pub-id-type="pmid">29351612</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0054">
      <label>54</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0054"><string-name><surname>Bottou</surname><given-names>L</given-names></string-name>. <article-title>Large‐scale machine learning with stochastic gradient descent</article-title>. <source>Proceedings of COMPSTAT</source>. <year>2020</year>:<fpage>177</fpage>‐<lpage>186</lpage>.</mixed-citation>
    </ref>
    <ref id="cam44717-bib-0055">
      <label>55</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0055"><string-name><surname>Roberts</surname><given-names>SA</given-names></string-name>, <string-name><surname>Gordenin</surname><given-names>DA</given-names></string-name>. <article-title>Clustered and genome‐wide transient mutagenesis in human cancers: hypermutation without permanent mutators or loss of fitness</article-title>. <source>Bioessays</source>. <year>2014</year>;<volume>36</volume>:<fpage>382</fpage>‐<lpage>393</lpage>.<pub-id pub-id-type="pmid">24615916</pub-id></mixed-citation>
    </ref>
    <ref id="cam44717-bib-0056">
      <label>56</label>
      <mixed-citation publication-type="journal" id="cam44717-cit-0056"><string-name><surname>Alexandrov</surname><given-names>L</given-names></string-name>, <string-name><surname>Jones</surname><given-names>P</given-names></string-name>, <string-name><surname>Wedge</surname><given-names>D</given-names></string-name>, et al. <article-title>Clock‐like mutational processes in human somatic cells</article-title>. <source>Nat Genet</source>. <year>2015</year>;<volume>47</volume>:<fpage>1402</fpage>‐<lpage>1407</lpage>.<pub-id pub-id-type="pmid">26551669</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
